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ABSTRACT  Over  the  last  20  years  it  has  been  realised  that  neonates,  infants  and  children experience  pain  and  considerable  stress  responses  to  surgical  and  medical procedures  which  are  harmful  and  cause  fear,  anxiety  and  distress(Walker, 2008).  
This  thesis will  describe  a  body  of work  published  since  1992 whose  aim  has been  to  improve  several  aspects  of  pain management  for  children  in  terms  of both  efficacy  and  safety.  The  studies  encompass  research  into  the  four  main classes  of  analgesics  used  in  paediatric  clinical  practice,  namely  local anaesthetics,  opioids,  non‐steroidal  anti‐inflammatory  drugs  (NSAIDs)  and paracetamol.  In addition,  control of  the  stress  responses  to  tracheal  intubation and  to  surgery  has  been  studied  with  the  availability  of  newer  potent  short‐acting opioid agents and the anaesthetic agent propofol. The total body of work described  covers 41 peer  reviewed publications with 14  index papers  selected for more detailed consideration. 
Local anaesthetics 
Several studies included in this thesis demonstrate the efficacy and safety of local anaesthetics in children.   
The optimum dose of the amide local anaesthetic, lignocaine, was determined for preventing pain on intravenous injection of propofol in children(Cameron et al., 1992) and this resulted in the widespread adoption of propofol as an induction agent. Several studies of propofol in children were conducted and this led to the 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development of more accurate computer‐controlled delivery for maintenance of anaesthesia  in  children  down  to  age  1  year(Morton  et  al.,  1988,  Marsh  et  al., 1990, Morton, 1990a, Marsh et al., 1991, Doyle et al., 1993c, Runcie et al., 1993, Morton, 1998b, Varveris and Morton, 2002).  
Topical  amethocaine  (as  a  gel  and  as  a  phase‐change  patch) was  evaluated  in children(Doyle et al., 1993a, Lawson et al., 1995, Lawson and Morton, 1998) and found to have a significantly more rapid onset of action than EMLA cream. This gel is now widely used in the UK.  
For  nerve  block,  the  efficacy  and  safety  of  fascia  iliaca  compartment  block  in children was demonstrated(Doyle et al., 1997) and the additional safety margin provided  by  adding  the  vasoconstrictor  adrenaline  to  the  local  anaesthetic solution  was  proved  by  very  low  peak  plasma  concentrations  of  local anaesthetic.    This  was  also  demonstrated  for  caudal  epidural  blockade  in infants(Hansen et al., 2001). 
New amide local anaesthetics were introduced in the last decade and ropivacaine was shown to be safe and effective for caudal epidural blockade in children(Ivani et  al.,  1998a).    A  collaboration  with  Strathclyde  University  led  to  the development  of  a  new  micro‐assay  method  for  measurement  of  local anaesthetics  in  small  volumes  of  plasma  with  applicability  to  neonatal  age groups  of  patients where  ethically  allowable  blood  sampling  volumes  are  very small(Stumpe et al., 2000). 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Opioids 
The  technique  of  patient‐controlled  analgesia  was  studied  in  children with  an open  feasibility  trial  in 1990(Lawrie et al., 1990) using conventional electronic syringe  pumps  and  a  further  innovative  study  of  a  disposable  elastomeric reservoir  device  in  1992(Irwin  et  al.,  1992).  The  optimum  regimen  for  PCA  in children was determined by a series of studies(Doyle et al., 1994a, Doyle et al., 1993d,  Doyle  et  al.,  1994c,  Munro  et  al.,  2002)  and  a  subsequent  trial demonstrated  that PCA could be delivered by  the subcutaneous  route(Doyle et al.,  1994b).    A  further  collaboration  with  Strathclyde  produced  a  microassay method  for  morphine  and  metabolites(Watson  et  al.,  1995).  These  studies showed  that  PCA  is  very  efficacious  and  safe  for  perioperative  pain  conrol  in children  from  age  5  years  upwards  and  this  technique  is  now  in  routine  use worldwide(Walker,  2008, APAGBI,  2008, Morton, 2007,  Lonnqvist  and Morton, 2005b). 
NSAIDs and Paracetamol 
Following the demonstration of the utility of PCA in children, the technique was used to assess the analgesic efficacy of the NSAID diclofenac and paracetamol in children(Morton  and O'Brien,  1999).  This  showed diclofenac  to be particularly efficacious  in  producing  a  40%  morphine‐sparing  effect  in  children.  An innovative  study  of  NSAID  eye  drops  showed  them  to  be  as  effective  as  local anaesthetic  eye  drops  for  providing  analgesia  after  strabismus  surgery  in children(Morton et al., 1997). 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Dosing regimens for paracetamol have evolved in the last decade based on better information  on  developmental  pharmacokinetics  and  elucidation  of  the mechanism of action(Arana et al., 2001, Ottani et al., 2006, Pickering et al., 2006, Anderson and Palmer, 2006). There is renewed interest in this decade with the availability of new IV formulations of this old drug.  In 1999(Hansen et al., 1999) we  contributed  to  the  PK  data  for  paracetamol  in  neonates  and  infants which was  subsequently  used  by  authors    from  New  Zealand  to  determine  the population PK parameters in this young age group(Anderson and Palmer, 2006).  We collated the knowledge on dosing regimens in 2001 in a review(Arana et al., 2001) which has informed the current recommendations in the BNFC.  A further collaboration with Strathclyde University led to the development of a microassay for paracetamol and  its metabolites  from blood spots which has been taken up by  Medecins  Sans  Frontieres  as  a  possible  method  to  use  in  the  field  in developing  countries(Oliveira  et  al.,  2002).  The  morphine‐sparing  efficacy  of paracetamol  was  shown  to  be  less  than  that  due  to  diclofenac  in  the  study mentioned above under NSAIDs(Morton and O'Brien, 1999).  
Controlling the stress response 
Noxious  stimuli  produce  a  stress  response.  A  series  of  studies  has  shown  that using short acting opioids, tracheal intubation could be safely performed without the  aid  of  muscle  relaxant  drugs  in  children(Steyn  et  al.,  1994,  O'Brien  et  al., 1998,  Robinson  et  al.,  1998).  This  technique  is  now  widely  practiced.  Two studies  explored methods  to  reduce  the  stress  response  to open heart  surgery with  cardiopulmonary  bypass,  one  of  the  most  potent  surgical  stressors. Propofol  anaesthesia  was  shown  to  significantly  ameliorate  this 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response(Laycock et al., 1992) and the newer opioid remifentanil was shown to be as efficacious as the older drug fentanyl for this purpose(Bell et al., 2004). 
 
 
Audit, guidelines and protocols 
Two  major  analgesic  techniques  have  been  audited  in  large  national  projects looking  at  the  risk  of  epidural  infusions  in  children(Llewellyn  and  Moriarty, 2007)  and  opioid  infusion  techniques  in  children  (Morton,  2008c)  and  the results show these techniques to be of comparable safety. The evidence from the past  20  years  has  recently  been  synthesised  into  a  clinical  guideline  for management  of  postoperative  and  procedural  pain  in  children  which  has highlighted  good  practice  based  on  high  quality  evidence  but  also  revealed  a paucity of evidence in some fields(APAGBI, 2008). Guidelines for safer paediatric procedural sedation practice  is also described(SIGN, 2004, Playfor et al., 2006). The  implementation of guidelines relies on the development of a  local protocol and  the  evolution  of  the  acute  pain  relief  service  protocol  in  Glasgow  is described.(Morton, 2008a) 
  8 
Acknowledgements 
 
I wish  to dedicate  this  thesis  to  the memory of my  son Christopher and  to my father and mother.  
I want  to  thank my wife  Sue, my  son Andrew  and my  daughter  Kate  for  their support.  
I  also  thank  Professors  John  Kinsella  and  Gavin  Kenny  for  encouraging me  to complete  the  thesis  and  to  colleagues  in  Dundee,  Montreal  and  Glasgow  who have worked so patiently with me over the years.  
I  want  to  pay  a  particular  tribute  to  the  paediatric  pain  nurses  at  the  Royal Hospital for Sick Children, Yorkhill, Glasgow (Susan Aitkenhead, Kay Trower and Margaret  McCulloch)  who  have  taken  up  the  challenge  of  starting  and maintaining  a  new  clinical  service  which  performs  at  an  exceptionally  high standard and is regarded as a model service.  
Most of all, this work is dedicated to the children and families who allowed me to include them in research studies  in a selfless, altruistic way.  I know the results have now benefitted thousands of children across the world as pain management has been given a much higher priority by all who care for children. 
 
  9 
THESIS OUTLINE 
• CHAPTER 1    
Paediatric  pain  management  has  developed  in  the  last  20  years  in  the light of greater understanding of  the development of  the pain pathways, availability  of  new  drugs  and  research  in  paediatric  pharmacology. Organisation  of  the  infrastructure  to  deliver  effective  pain  assessment and  pain  management  has  also  occurred  in  the  last  15  years  with  the development  of  paediatric  acute  pain  teams.  These  developments  are reviewed to place the current thesis in context. 
• CHAPTER 2 
Studies  of  opioid  pharmacokinetics,  pharmacodynamics  and pharmacogenomics  in  children  are  still  ongoing  and  a  study  of  a  new micro‐assay  method  for  measuring  morphine  and  its  metabolites  is described(Watson  et  al.,  1995).  A  new  microassay  method  for measurement of paracaetamol and  its metabolites  in blood spots  is also described  which  may  have  utility  in  neonates  and  in  difficult environments(Oliveira et al., 2002). 
• CHAPTER 3 
Local  anaesthesia  techniques  have wide  applicability  in  paediatrics  and are  the  foundation  of  the  control  of  procedural,  intraoperative  and 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postoperative pain.  This chapter describes the first comparative study of amethocaine gel with EMLA cream  in  children(Lawson et  al.,  1995),  the first  study  of  an  innovative  phase‐change  patch  formulation  of amethocaine  in  children  (Doyle  et  al.,  1993a)  and  two  studies  of  local anaesthetic  pharmacokinetics  and  dynamics  in  children(Doyle  et  al., 1997,  Hansen  et  al.,  2001).  In  addition,  the  minimal  effective  dose  of lignocaine to abolish injection pain due to propofol is described(Cameron et  al.,  1992).  This  allowed more widespread  adoption  of  propofol  as  an anaesthetic agent in children. 
• CHAPTER 4 
Opioid  techniques  and  regimens  suitable  for  safe  use  in  children  have been  developed  and  this  chapter  describes  one  index  study  from  a portfolio of studies of patient‐controlled analgesia in children(Irwin et al., 1992).  
• CHAPTER 5 
Paracetamol  and NSAIDs  are  commonly  used  but  the  evidence  base  for dosing  has  until  recently  been  poor,  especially  in  young  infants  and neonates. A study of paracetamol pharmacokinetics is presented(Hansen et  al.,  1999)  which  contributed  to  more  rational  dosing  regimens  in neonates, infants and children. The analgesic efficacy of paracetamol and the  NSAID  diclofenac was  assessed  in  a  study  of  “morphine‐sparing”  in children(Morton and O'Brien, 1999).  
• CHAPTER 6 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Stress  control  for  paediatric  surgery  is  particularly  important  when surgery  is major  in nature  and when patients  are  young or  critically  ill.  Two studies of control of the stress response to paediatric cardiac surgery are  described(Laycock  et  al.,  1992,  Bell  et  al.,  2004).  Development  of techniques of stress free tracheal intubation without the need for muscle relaxants has occurred with the advent of new short‐acting opioids. Two studies describe these techniques in children(Steyn et al., 1994, Robinson et al., 1998). 
• CHAPTER 7 
After a large national audit of epidural infusion analgesia in children, the author has led a similar audit of opioid infusion analgesia techniques and the  interim  results  are  described  in  this  chapter(Morton,  2008c).  The importance of integration and synthesis of the evidence about paediatric analgesia  into  clinical  guidelines  and  protocols  managed  by  paediatric acute pain teams is emphasised(APAGBI, 2008, Morton, 2008a).  
• CHAPTER 8 
The scientific basis  for  improving pain control  for children  is now much more robust and has assumed a much higher priority in care of children undergoing medical and surgical procedures. 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IMPLICATIONS OF 
THESIS FOR CLINICAL 
PRACTICE  The output  from  these  studies has provided  some of  the evidence base  for  the formation  of  protocol‐driven  paediatric  acute  pain  teams,  a  major  change  in clinical  practice  in  the UK  and world‐wide.  There  are  now 22  paediatric  acute pain  teams  in  the UK with  the Glasgow  team second  to be established and  the first in Scotland. Pain assessment and pain management of children is now given a  much  higher  priority(Walker,  2008,  APAGBI,  2008).  Better  and  safer  pain control  has  led  to  significant  developments  in  paediatric  day  case surgery(Lonnqvist  and  Morton,  2006).  National  evidence‐based  guidelines  for safer paediatric procedural sedation and analgesia and paediatric postoperative analgesia have now been produced and the author has had a significant input to these(SIGN, 2004, Playfor et al., 2006, APAGBI, 2008). Safety has been tested for the most  invasive  analgesic methods  by  recent UK National  Audits  of  epidural infusion analgesia in children(Llewellyn and Moriarty, 2007) and opioid infusion techniques in children(Morton, 2008c) which the author has contributed to and run.  
The  newer  amide  local  anaesthetics  are  now widely  used  in  children(Morton, 2000, Bosenberg et al., 2005, APAGBI, 2008) and the ester  local anaesthetic gel amethocaine  is  widely  used  due  to  its  proven  rapid  onset  of  action(APAGBI, 2008). 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Tracheal  intubation  using  relaxant‐free  techniques  is  now widely  practiced  in paediatric  anaesthesia  and  stress  control  techniques  for paediatrics  are widely accepted  as beneficial  especially  in  the  youngest  age  groups undergoing major surgery.  
Pain management for children has improved. 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INTRODUCTION 
(APAGBI,  2008,  Walker,  2008,  Morton,  2007,  Harvey  and 
Morton, 2007, SIGN, 2004, Morton, 1998a) 
Pain  is  defined  by  the  International  Association  for  the  Study  of  Pain  as  “An 
unpleasant  sensory and emotional  experience associated with actual or potential 
tissue  damage  or  described  in  terms  of  such  damage”.  There  are  long‐term psychological  and  physical  consequences  of  inadequate  pain  control  in  all  age groups (Tables 1.1 )(Walker, 2008, Notcutt, 1997).  
TABLE 1.1: ADVERSE EFFECTS OF PAIN 
PSYCHOLOGICAL  PHYSICAL 
anxiety and fear  
(now and in future) 
increased death rate after major surgery 
nightmares and sleep 
disturbance 
increased morbidity 
behavioural and personality 
disturbance 
respiratory: hypoxaemia, impaired 
respiratory function, decreased cough and 
cooperation with physiotherapy, increased 
secretion retention, atelectasis, infection 
disruption of schooling  cardiovascular: sympathetic stimulation 
(increased heart rate and blood pressure, 
vasoconstriction, altered regional blood flow, 
increased oxygen consumption), risk of 
venous thrombosis 
development of vicious cycles 
to chronic pain 
stress response: stress hormone surges, 
disordered electrolyte and fluid balance, high 
blood sugar level, osmotic diuresis in 
neonates, depressed immune function 
  cerebral: increase in intracranial pressure, 
increased risk of intraventicular 
haemorrhage or cerebral ischaemia in 
premature neonates 
  musculo­skeletal: muscle spasms, immobility, 
delayed mobilisation  
  visceral: slowing of gastrointestinal and 
urinary function 
  wound: decreased healing 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LONG­TERM EFFECTS OF PAIN IN EARLY LIFE 
alteration in behavioural responses(Grunau et al., 2006) 
change in baseline sensory function(Schmelzle­Lubiecki et al., 2007) 
enhanced responses to future pain(Taddio et al., 1997, Hermann et al., 2006) 
increased analgesic requirements(Peters et al., 2005)  
It  is  now  accepted  that  for  moral,  humanitarian,  ethical  and  physiological reasons,  pain  should  be  anticipated  and  safely  and  effectively  controlled  in  all children, whatever their age, maturity or severity of illness (Table 1.2)(Walco et al., 1994).  
 
TABLE 1.2: BENEFITS OF PAIN PREVENTION AND CONTROL 
PSYCHOLOGICAL  PHYSICAL 
patient satisfaction, reduced anxiety 
and fear, normalise sleep and 
behaviour, avoidance of vicious 
cycles to chronic pain 
lower mortality after major surgery, 
decreased cardiorespiratory 
complications, earlier weaning from 
respiratory support, decreased 
wound and respiratory infection 
rates, earlier mobilisation and 
discharge, earlier return of visceral 
function and oral intake, better fluid 
and electrolyte homeostasis, 
reduced cerebral complications 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Techniques of pain control should be applied in advance of the painful stimulus wherever  possible(RCPCH,  1997,  Notcutt,  1997).  This  pre‐emptive  approach helps  to  minimise  the  emotional  problems  of  fear  and  anxiety,  prevents  the “wind‐up”  phenomenon  of  central  nervous  system  sensitisation  to  noxious stimuli  and  tissue  release  of  pain  mediators,  ameliorates  the  stress  response, reduces  the  intraoperative  anaesthetic  requirement  and  subsequent  analgesic requirements(Walker, 2008, APAGBI, 2008).  
A multimodal approach to preventing pain using local anaesthetics, opioids, non‐steroidal anti‐inflammatory drugs (NSAIDs), sedation and non‐drug methods in a safe  and  effective  planned way,  tailored  to  each  individual  child’s  needs  is  the basis of acute pain prevention(Morton, 1998a, Morton, 1993). This requires that pain is assessed regularly and the assessment is linked to action to maintain pain control with minimal adverse effects (APAGBI, 2008, RCN, 1999).  
Pain  control  techniques  are  not  risk‐free  (Table  1.3)(Llewellyn  and  Moriarty, 2007, Morton, 2008c) 
TABLE 1.3: RISKS OF PAIN CONTROL TECHNIQUES 
TECHNIQUE  INFUSION 
EQUIPMENT 
DRUG 
needle damage, 
misplacement,  
haematoma,  
cerebrospinal fluid leak, 
infection,  
urinary retention,  
itch,  
extravasation of drug,  
depot effect with 
subcutaneous/intramuscular 
route 
over­infusion, 
under­infusion, 
gravity free­flow, 
reflux,  
electronic 
Interference 
allergy,  
overdose, 
underdose, 
prescription error, 
dilution error, 
wrong drug,  
adverse effect 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Preparing  the  child  and  family  in  advance  with  good  written  and  verbal information and careful matching of the analgesic technique to the child will help to reduce fear, anxiety and correct misconceptions. This approach should apply to all painful procedures however minor or major and often means placing pain prevention higher up the list of priorities in each child’s overall plan of care. This requires  good  education  of  staff,  parents  and  children,  forward  planning  and organisation.  A  paediatric  pain  management  service  has  been  found  to  be effective  in  achieving  consistent  standards  of  efficacy  and  safety  (Table 1.4(Lloyd‐Thomas  and  Howard,  1994,  Howard,  1996,  McKenzie  et  al.,  1997, RCPCH, 1997, Morton, 1998a, Finley and McGrath, 2001, APAGBI, 2008)). 
TABLE 1.4: ROLES OF A PAEDIATRIC PAIN MANAGEMENT SERVICE 
ORGANISATION  personnel, 24­hour cover, call­out 
and consultation system, good 
communication systems, equipment, 
teaching, clinic for complex/long­
term cases 
SERVICE DELIVERY  multidisciplinary personnel  
(pain nurse specialist, anaesthetist, 
pharmacist, physiotherapist, 
paediatrician, surgeon, psychologist, 
psychiatrist, play therapist, etc.), 
monitoring standard, equipment, 
follow­up system, daily senior 
anaesthetic input 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EDUCATION  program for anaesthetists, surgeons, 
paediatricians, emergency room 
staff, nurses, pharmacists, parents, 
children, management personnel 
AUDIT  efficacy, safety, adverse events, 
outcome, equipment, costs, 
efficiency, benefits, risks 
RESEARCH  drugs, equipment, monitoring 
 
Studies  have  shown  that  one  of  the  major  reasons  for  poor  paediatric  pain management  is  a  lack  of  education  of  staff,  parents  and  children.  Myths  and misconceptions  persist,  for  example  that  children  do  not  feel  pain  as much  as adults or are at risk of addiction if opioids are used. Many medical staff are still worried about the safety aspects of prescribing adequate doses of analgesia for children.  Medical  and  nursing  students  and  trainees  have  often  received  very little  formal  training  in  paediatric  pain  management  but  are  expected  to prescribe  and  administer  analgesia  to  children.  As  a  result,  staff  often  express undue concern about side effects and tend to use inadequate doses of analgesic drugs.  Fears  regarding  opioid  addiction  often  lead  to  a  change  to  a  weaker analgesic prematurely. Medical and nursing staff  tend to underestimate pain  in children  and  this  is  borne  out  by  studies  of  the  assessments  of  pain made  by children themselves of their pain experience when compared to the assessments made by parents or staff(RCN, 1999). Many staff still  feel  that pain can only be reduced but not controlled or prevented. 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Practice  can  be  changed  by  education.  This  is  illustrated  by  the  changes  in perception and practice amongst paediatric anaesthetists surveyed in 1988 and again  in  1995  (Table  1.5)(De  Lima  et  al.,  1996).  This  highlights  very  well  the evolution  of more  comprehensive  analgesic  prescribing  and more  appropriate use of local anaesthetics, opioids and NSAIDs.  
TABLE  1.5:  RESULTS OF  TWO  SURVEYS OF  PAEDIATRIC  ANAESTHETISTS’ 
PERCEPTIONS AND PRACTICE IN 1995 COMPARED WITH 1988(De Lima et 
al., 1996) 
  1988  1995 
% who thought neonates did not feel pain  13%  0% 
%  who  prescribed  opioids  for  neonates 
after major surgery 
10%  91% 
%  who  used  local  anaesthetic  block  or 
infiltration in newborns 
27%  88% 
%  who  used  local  anaesthetic  for  minor 
surgery 
27%  99% 
 
Information  should  be  provided  for  children  and  families  in  an  appropriate language and in written and verbal forms. Parents may ask about the drugs their child may  receive and should be given detailed explanations about  the options available. The benefits  and  risks  should be  clearly  explained.  If  the  child  is  old 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enough  to  be  consulted  then  they  can  be  asked  about  their  preferences  and should receive an explanation in a form relevant to their age and development. A specific  plan  of  analgesia  can  then  be  tailored  to  the  needs  of  each  individual child(Howard, 1996). If parents are familiar with a particular technique such as patient‐controlled  analgesia,  they  can  encourage  their  children  to  use  the technique  more  appropriately.  Clear  information  should  help  to  decrease  the level of anxiety and in turn this reduces the analgesic requirement. Parents can also help with assessment of their child, particularly when the child has a mental handicap  or  has  behavioural  or  developmental  problems.  The  parent  is  often best at distinguishing the signs of pain in their child and should be encouraged to communicate with staff so that effective analgesia can be maintained. Although a high  proportion  of  parents  are  resident  with  their  child  in  hospital,  they  are more  likely to be confident about  leaving their child  in the care of others  if  the child  is  comfortable.  A  family  centred  approach  to  the  care  of  children  is  very helpful  in  encouraging  the  child  back  towards  their  normal  environment  and level of function(RCPCH, 1997, Walker, 2008).  
 
PLANNING PAIN MANAGEMENT 
The  main  factors  to  consider  when  planning  individualised  pain management(Howard, 1996) are listed in Table 1.6. 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TABLE 1.6: FACTORS IN PLANNING PAIN MANAGEMENT 
age, maturity, physical status, mental status 
severity of illness 
medical factors: eg. organ dysfunction, asthma, epilepsy, reflux 
surgical factors: eg. extent and nature of surgery 
anaesthetic factors: eg. airway abnormality, suitability or contraindication 
to particular analgesic technique 
expected pain severity and duration 
pain assessment method and training of assessor 
past pain experience 
child / parental preferences 
psychological factors 
medical environment: day case, out­patient, a & e, general ward, HDU, ITU 
can minimum monitoring standard be met: nurse dependency, assessment 
of efficacy, monitoring and management of adverse effects 
anticipated pathway to recovery 
continuing pain control   
So, prevention of pain and good pain control are high priorities when dealing with children. The benefits of pain control techniques, when properly selected and  applied,  outweigh  the  risks.  Education  of  children  parents  and  staff improves the success and safety of pain control and to ensure comprehensive pain prevention and control requires planning and organisation. 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IMPROVEMENTS IN THE EVIDENCE­BASE FOR PAEDIATRIC PAIN 
MANAGEMENT  
Recently the evidence underpinning the management of paediatric pain has been collated and evaluated in a number of evidence‐based guidelines and systematic reviews. These are presented by analgesic technique (RCA, 1998, ANZCA, 2005, Ansermino et al., 2003, Playfor et al., 2006, Moiniche et al., 2003) or by surgical or medical procedure(APAGBI, 2008). This  allows  logical  selection of  analgesia for  an  individual  child,  undergoing  a  specific  procedure  in  a  given  clinical setting(Walker  et  al.,  2006).  In  addition,  evidence‐based  guidelines  for procedural  sedation  of  children  have  been  developed  in  Scotland(SIGN,  2004).  These guidelines cover all age groups from neonates to adolescents and settings as diverse as clinic, accident and emergency unit, critical care unit, general ward, operating  theatre  and  postoperative  ward.  For  neonates  in  particular,  a  large literature  has  developed  to  review  analgesic  techniques  based  upon  better understanding  of  the  developmental  aspects  of  pain  physiology  and  analgesic pharmacology(Walker, 2008) but also due to better appreciation of the need for good studies in this age group(Anand et al., 2005a).  
 
  27 
IMPROVEMENTS IN THE UNDERSTANDING OF DEVELOPMENTAL 
ASPECTS OF PAIN AND ANALGESIA 
 
Developmental physiology of pain There have been huge advances in understanding of the development of the pain pathways,  their  function  and  the  changes  in  distribution  of  receptors  in  early life(Fitzgerald, 2005, Baccei and Fitzgerald, 2006, Walker, 2008). This has in turn helped understanding of the changes in pharmacodynamics of analgesics during development and the short‐ and long‐term consequences of pain in early life (see Table 1.1). In the periphery, repeated noxious stimuli produce local sensitisation eg.  after  heel‐stick  blood  sampling  in  pre‐term  neonates.  In  the  spinal  cord, excitatory mechanisms mature  earlier  than  inhibitory mechanisms  resulting  in generalised, mass responses to stimuli that are not well directed and have a low threshold to trigger them, but yet match the stimulus intensity.  These stimuli get through even to the immature cortex (Bartocci et al., 2006) 
Developmental pharmacology of analgesics Greater  understanding  of  the  effects  of  size  and  developmental  stage  upon pharmacokinetics and dynamics of analgesics has mainly occurred in the last 10 years  and  this  has  resulted  in  much  more  logical  and  accurate  dosing  in children(Berde  and  Cairns,  2000,  Anderson  and  Meakin,  2002,  Anderson  and Holford,  2008).  Data  on  developmental  changes  in  body  composition,  organ function,  plasma  protein  binding  and  concentration,  and  elimination  enzyme systems and pathways are now available for most analgesics in common use in children. 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Stress response and its control The importance of the stress response to noxious stimuli has been increasingly recognised in paediatrics  for around 20 years (Aynsley‐Green et al., 1995, Wolf et  al.,  1998,  Anand  et  al.,  1987,  Anand  and  Aynsley‐Green,  1988,  Anand  et  al., 1988, Anand and Carr, 1989, Morton, 1989, Anand et al., 1990, Morton, 1990b, Wolf,  1993,  Wolf  et  al.,  1993,  Glover  and  Giannakoulopoulos,  1995,  Aynsley‐Green, 1996, Wolf, 1997, Bell et al., 2004, Humphreys et al., 2004, Stumpe et al., 2006, Grunau et al., 2005). Amelioration of the stress response to noxious stimuli is beneficial  for children especially young  infants(Anand et al., 2006, D'Apolito, 2006) and those undergoing major surgery(Bouwmeester et al., 2001, Bozkurt, 2002, Bozkurt et al., 2004, Bozkurt et al., 2003). A common stressor in neonates and children is tracheal intubation and, with the availability of new anaesthetic agents and opioids, the possibility of minimising the stress response to tracheal intubation without the use of muscle relaxants has developed from experience in adult practice(Morton and Hamilton, 1986, Steyn et al., 1994, O'Brien et al., 1998, Robinson et al., 1998, Anand et al., 2005b, Aranda et al., 2005, Lago et al., 2005, McGrath, 2005, D'Apolito, 2006, Dempsey et al., 2006, Milesi et al., 2006, APAGBI, 2008, Welzing and Roth, 2006, Playfor et al., 2006). 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CHAPTER 2: 
 
IMPROVING ANALGESIC 
ASSAYS 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2.1 Microassay of analgesics 
2.1.1  Watson  DG,  Su  Q,  Midgley  JM,  Doyle  E,  Morton  NS.  Analysis  of 
unconjugated  morphine,  codeine,  normorphine  and  morphine  as 
glucuronides  in  small  volumes  of  plasma  from  children.  Journal  of 
Pharmaceutical & Biomedical Analysis. 1995 Jan;13(1):27­32.  
Abstract 
A  sensitive  method  for  the  analysis  of  unconjugated  morphine,  codeine, 
normorphine  and  total  morphine  after  hydrolysis  of  glucuronide  conjugates  is 
described.  The  method  was  applicable  to  50­microliter  volumes  of  plasma.  The 
analytes were converted to heptafluorobutyryl (HFB) derivatives before analysis by 
gas  chromatography­negative  ion  chemical  ionization  mass  spectrometry. 
Morphine and codeine were quantified against their [2H3]­isotopomers. Linearity, 
precision and accuracy were quite acceptable (in the 10(­10)­10(­9) g range), and 
the absolute limits of detection were < 1 pg. 
2.1.2  Oliveira  EJ,  Watson  DG,  Morton  NS.  A  simple  microanalytical 
technique  for  the determination of paracetamol and  its main metabolites 
in blood spots.  Journal of Pharmaceutical & Biomedical Analysis. 2002 Jul 
31;29(5):803­9. 
Abstract 
The  use  of  blood  spot  collection  cards  is  a  simple  way  to  obtain  specimens  for 
analysis of drugs with a narrow therapeutic window. We describe the development 
and  validation  of  a  microanalytical  technique  for  the  determination  of 
paracetamol and  its  glucuronide and  sulphate metabolites  from blood  spots. The 
method is based on reversed phase high­performance liquid chromatography with 
ultraviolet detection. The limit of detection of the method is 600 pg on column for 
paracetamol.  Intra­  and  inter­day precision  of  the  determination  of  paracetamol 
was  7.1  and  3.2%  respectively.  The  small  volume  of  blood  required  (20 microl), 
combined  with  the  simplicity  of  the  analytical  technique  makes  this  a  useful 
procedure for monitoring paracetamol concentrations. The method was applied to 
the analysis of blood spots taken from neonates being treated with paracetamol. 
 
Discussion When  these  studies  were  developed,  there  was  interest  in  reinvestigating existing medicines  in  children  and  ethical  constraints  on  the  volume  of  blood sampled  from  small  children  for  the  purposes  of  research.  The  aim  was  to develop accurate microassay methods for analgesics in children  (Watson et al., 1995,  Stumpe  et  al.,  2006,  Oliveira  et  al.,  2002) with  a  view  to  applying  these techniques  to  infants  and  neonates.  With  highly  sensitive  and  specific  assay 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techniques,  it  has  been  possible  to  measure  analgesics  and  their  main metabolites and binding proteins  in  tiny volumes of plasma and  in dried blood spots, the latter from a volume of approximately 8 microlitres of blood. 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3.1 Local anaesthesia to abolish injection pain due to propofol in 
children 
3.1.1 Cameron E,  Johnston G, Crofts  S, Morton NS. The minimum effective 
dose  of  lignocaine  to  prevent  injection  pain  due  to  propofol  in  children. 
Anaesthesia. 1992 Jul;47(7):604­6.  
Abstract 
In a  single­blind study of 100 children aged 1  to 10 years,  the minimum effective 
dose of lignocaine required to prevent injection pain due to propofol was 0.2 mg/kg 
when veins on the dorsum of the hand were used. This is more than twice the adult 
value.  We  concluded  that  injection  pain  should  not  limit  the  use  of  propofol  in 
children  if  an  adequate  amount  of  lignocaine  is  mixed  immediately  prior  to 
injection. 
 
Discussion 
This  simple  study was  undertaken  at  a  time when  propofol  was  just  entering clinical practice in paediatric anaesthesia(Morton et al., 1988). It was recognised that propofol caused injection pain in up 85% of children(Valtonen et al., 1989) and  this  undoubtedly  was  limiting  the  clinical  use  of  propofol  in  paediatric anaesthesia at that time. In adult practice, lignocaine admixture was shown to be effective(Scott  et  al.,  1988,  Stafford  et  al.,  1991)  while  in  a  pilot  study  of  50 unpremedicated children, lignocaine 1mg/kg was found to abolish injection pain in  veins  on  the  dorsum  of  the  hand(Morton,  1990a).  This  dose  was  chosen empirically and after discussion with the ethics committee, a study was designed to  define  the  minimum  effective  dose.  One  hundred  children  aged  1‐10  years were given propofol 3mg/kg with stepwise‐reducing doses of lignocaine starting at  the  empirical  high  dose  of  1mg/kg  and,  if  pain  free,  successive  children received a decrement of  dose of 0.1mg/kg . If pain was noted, then an increment of 0.1 mg/kg was used in the next child.  Using this “up‐and‐down” technique, a 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threshold  for  effective  dosing  of  lignocaine  was  defined  in  children  when injecting 1% propofol  into  the veins on  the dorsum of  the hand.   No child who received 0.2mg/kg or more of added lignocaine experienced pain (Figure 3.1). 
 
Figure  3.1:  The  minimum  effective  dose  of  lignocaine  was  found  to  be 
0.2mg/kg for children age 1­10 years when injecting 1% propofol into the 
veins on the dorsum of the hand. 
This minimum effective dose was noted to be approximately twice that of adults (Stafford et al., 1991) and also somewhat higher than the dose described in other paediatric studies at  the  time which had  found unsatisfactory rates of  injection pain of 29‐60% (Patel et al., 1988, Morton et al., 1988). This study also showed that when injection pain occurred in younger children tended to be more severe. 
Clinical implications 
This  study  demonstrated  a  simple  method  of  abolishing  injection  pain  due  to propofol  in  children  and  encouraged  increased  use  of  propofol  by  paediatric 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anaesthetists. Propofol  is now routinely used  for  induction and maintenance of anaesthesia  in  children(Morton,  2008d, Marsh  et  al.,  1991, Doyle  et  al.,  1993c, Varveris  and Morton,  2002,  BNFc,  2008,  Morton,  1998b,  Eyres,  2004,  Morton, 2008b).
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3.2 Topical local anaesthesia with amethocaine in children 
3.2.1  Lawson  RA,  Smart  NG,  Gudgeon  AC,  Morton  NS.  Evaluation  of  an 
amethocaine  gel  preparation  for  percutaneous  analgesia  before  venous 
cannulation  in  children.  British  Journal  of  Anaesthesia.  1995 
Sep;75(3):282­5.  
We have evaluated the efficacy and safety of a preparation of 4% amethocaine gel 
in alleviating the pain of venous cannulation in children. In an initial open study of 
148 children, clinically acceptable anaesthesia was achieved  in 92% of cases. The 
preparation was then compared with 5% EMLA cream in a single­blind study in 94 
patients  using  an  application  time  of  40  min.  We  found  clinically  acceptable 
conditions in 85% of patients receiving amethocaine gel compared with 66% in the 
EMLA  group.  There  were  no  significant  adverse  effects  noted  in  each  group, 
although  37%  of  those  children  treated  with  amethocaine  gel  showed  localized 
erythema  at  the  application  site.  The  results  suggest  that  amethocaine  gel  has 
greater  efficacy  and  a  faster  onset  time  than  EMLA  cream  when  used  for  this 
purpose in children. 
3.2.2 Doyle  E,  Freeman  J,  Im NT, Morton NS.  An  evaluation  of  a  new  self­
adhesive patch preparation of amethocaine for topical anaesthesia prior to 
venous cannulation in children. Anaesthesia. 1993 Dec;48(12):1050­2.  
Abstract 
A new preparation of amethocaine in the form of a self­adhesive patch, designed to 
provide topical cutaneous anaesthesia prior to venous cannulation, was evaluated 
in an open study of 189 children. The new preparation of amethocaine was in place 
for a mean time of 48 min (SD 3.9). Eighty percent of patients had a satisfactory 
degree of analgesia  for  venous  cannulation. Nine percent of patients  experienced 
moderate  pain  and  11%  experienced  severe  pain  during  venous  cannulation.  In 
26% of patients there was slight (24%) or moderate (2%) erythema at the site of 
application,  and  in  5%  slight  oedema was  noted  at  the  site  of  application.  Eight 
percent of patients had slight  itching and 1% had moderate  itching at  the site of 
application.  There  was  a  clinical  impression  that  venous  dilatation  made 
cannulation  easier  than  with  EMLA  cream.  These  results  suggest  that  this 
convenient  preparation  of  amethocaine  is  highly  effective  at  providing  adequate 
topical cutaneous anaesthesia with a short onset time and a low incidence of minor 
side effects with no evidence of systemic toxicity.  
Discussion Topical  local  anaesthesia  of  the  skin  prior  to  needling  procedures  is  now accepted  as  the  standard  of  care  unless  there  are  specific  contraindications (APAGBI,  2008,  BNFc,  2008).  The  evidence  is  very  strong  (level  A)  for 
  37 
effectiveness  of  these  techniques  (APAGBI,  2008)  and  there  is  now a  choice of formulations  of  various  local  anaesthetics  available  (BNFc,  2008).    At  the  time these studies were carried out, only EMLA cream was available in the UK which is an eutectic mixture of  lignocaine and prilocaine with an onset  time of 40‐90 minutes  depending  on  the  site  of  application  and  the  age  and  ethnicity  of  the patient  (Sweetman,  2007,  BNFc,  2008,  Freeman  et  al.,  1993).  Amethocaine (tetracaine),  an  ester‐local  anaesthetic  agent,  is  highly  lipophilic  with  high affinity  for  neural  tissue  and  seemed  therefore  to  have  potential  to  penetrate intact  skin  quickly  (McCafferty  et  al.,  1989).  Early  studies  showed  promising results in adults for venous cannulation (Molodecka et al., 1994) and in children for venepuncture (Woolfson et al., 1990).  The onset time appeared to be reliably quicker  than  EMLA  cream,  and  with  a  much  longer  duration  of  action  after removal,  probably  due  to  the  depot  of  amethocaine  in  the  stratum  corneum (McCafferty et al., 1989). The  first study was  therefore an open evaluation of a 4% w/w amethocaine gel formulation applied for 40‐60 minutes to the dorsum of  the  hand  for  venous  cannulation  in  children  age  3‐12  years  (Lawson  et  al., 1995).  The  aim was  to  judge  efficacy  and  safety  as  a  prelude  to  a  comparison with EMLA cream (Lawson et al., 1995).  The results showed amethocaine had a quicker  onset  of  action  and  was  more  efficacious  than  EMLA  cream  after  an application  time of 40 minutes, although more often produced erythema at  the application site.  
Amethocaine can also be formulated as a phase‐change patch and this had been successfully  evaluated  in  adults  (McCafferty  and  Woolfson,  1993).  The  self‐adhesive patch  incorporates a  thin  film of  anhydrous amethocaine base which, 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upon wetting and reaching body temperature, changes from solid to liquid phase and then more rapidly penetrates  intact skin (McCafferty and Woolfson, 1993). This  patch  applied  for  an  average  time  of  48  minutes  produced  satisfactory analgesia  for  venous  cannulation  in  80% of  children  studied with  erythema  at the application site in about a third of children (Doyle et al., 1993a).  
There were no  cases  of  systemic  toxicity with  these  amethocaine  formulations which is reassuring for an ester local anaesthetic. Esterases in the skin and blood lead  to  rapid metabolism with  very  low  plasma  concentrations  and  the  depot formed in the stratum corneum results in slow sustained release of the drug thus avoiding high peak plasma concentrations. 
These  studies were not  designed  to  assess duration of  analgesia  after  removal but  amethocaine  has  been  shown  to  produce  several  hours  of  analgesia  after removal due to the depot effect noted above (Small et al., 1988). 
Clinical implications Amethocaine gel has been widely adopted for needling procedures in children in the  UK  since  this  study  was  conducted  and  has  a  product  licence  for  use  in infants and children (Sweetman, 2007, APAGBI, 2008, BNFc, 2008).  It has shown particular  utility  when  time  is  short  in  day  cases  and  in  the  emergency  or treatment room. The patch formulation has not been released commercially but recently  a  new  lignocaine/amethocaine  patch  incorporating  a  thermogenic  gel layer  has  been  marketed  which  shows  promise  in  further  speeding  onset  of analgesia. 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3.3 Pharmacokinetics of amide local anaesthetics in children 
3.3.1 Doyle E, Morton NS, McNicol LR. Plasma bupivacaine levels after fascia 
iliaca  compartment  block  with  and  without  adrenaline.  Paediatric 
Anaesthesia. 1997;7(2):121­4.  
Abstract 
Twenty children undergoing unilateral surgery on the thigh received a fascia iliaca 
compartment  block  using  2  mg/kg  of  bupivacaine  with  (Group  A)  or  without 
(Group P) adrenaline 1/200,000. Venous blood samples were taken as 5, 10, 15, 20, 
25,  30,  40,  50  and  60  min  after  injection  and  assayed  for  concentrations  of 
bupivacaine.  In  all  subjects  an  adequate  block  was  produced.  Plasma 
concentrations of bupivacaine  in Group P were  significantly higher  than  those  in 
Group A  (P < 0.05). The median maximum plasma concentration  (Cmax) was 1.1 
micrograms/ml  (range  0.54­1.29  micrograms/ml)  in  Group  P  and  0.35 
microgram/ml  (range  0.17­0.96  microgram/ml)  in  Group  A.  The  median  time 
taken to attain Cmax (Tmax) was 20 min (range 10­25 min) in Group P and 45 min 
(range 5­50 min) in Group A. The median time to first analgesia was 9.75 h (range 
3­15 h) in Group P and 10.5 h (range 2.5­21 h) in Group A. The study confirmed the 
efficacy of the fascia  iliaca compartment block in children and showed that when 
performed  with  2  mg/kg  of  bupivacaine  it  is  associated  with  plasma 
concentrations  of  bupivacaine  well  within  acceptable  limits.  The  addition  of 
adrenaline  1/200,000  to  the  local  anaesthetic  solution  reduces  the  maximum 
plasma concentration reached. 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3.3.2 Hansen TG, Morton NS, Cullen PM, Watson DG. Plasma concentrations 
and  pharmacokinetics  of  bupivacaine  with  and  without  adrenaline 
following  caudal  anaesthesia  in  infants.  Acta  Anaesthesiologica 
Scandinavica. 2001 Jan;45(1):42­7.  
Abstract 
BACKGROUND:  The  aim  of  this  study  was  to  determine  whether  the  use  of 
adrenaline 1/400000 added to 0.25% bupivacaine significantly delays the systemic 
absorption of the drug from the caudal epidural space in young infants. METHODS: 
Fifteen  infants  less  than  5  months  of  age  undergoing  minor  lower  abdominal 
procedures under a standardised general anaesthetic were randomised to receive a 
caudal block with either 0.25% plain bupivacaine 2.5 mg/kg (n=7) or bupivacaine 
0.25% with 1/400000 adrenaline (n=8). Blood samples were drawn at 30, 60, 90, 
180, 240 and 360 min according to the infant's weight and analysed for total and 
free  bupivacaine  concentrations  using  a  gas  chromatography­mass  spectrometry 
(GC­MS)  technique. RESULTS: The  total C(MAX) and T(MAX) were comparable  in 
both groups.  The  total  bupivacaine  concentration at  t=360 min was  significantly 
higher  in  the  "adrenaline"  group  compared  to  the  "plain"  group,  i.e.  a  median 
(range) 742 ng/ml (372­1423 ng/ml) vs. 400.5 ng/ml (114­446 ng/ml), P=0.0080. 
The  median  "apparent"  terminal  half­life  (t1/2)  was  significantly  longer  in  the 
"adrenaline" group (363 min; range 238­537 min) compared to the "plain" group 
(n=6)  (165  min;  range  104­264  min),  P=0.0087.  The  free  bupivacaine 
concentrations  (n=3  in  both  groups)  ranged  between  13  ng/ml  and  52  ng/ml, 
corresponding  to  a  percentage  of  free  bupivacaine  between  1.3%  and  6.7%. 
CONCLUSION:  The  addition  of  1/400.000  adrenaline  prolongs  the  systemic 
absorption of  caudally administered bupivacaine  in  infants  less  than 5 months of 
age. 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Discussion Local  anaesthetic  techniques  are  regarded  as  the  foundation  of  perioperative pain control in children (APAGBI, 2008) and single injection techniques are still the most commonly used (Morton, 1998a, Lonnqvist and Morton, 2005a, Morton, 2007). At the time these studies were conducted, bupivacaine was the usual local anaesthetic agent used in children but of course has been superceded by the new amide  local  anaesthetic  agents,  levobupivacaine  and  ropivacaine  (Sweetman, 2007, Morton, 2007, APAGBI, 2008, BNFc, 2008).   These studies were designed primarily  to  assess  the  plasma  concentration‐time  profiles  of  bupivacaine  in infants  and  children  after  caudal  or  fascia  iliaca  compartment  blocks  and  the influence  of  added  adrenaline  (Doyle  et  al.,  1997, Hansen  et  al.,  2001).  Caudal blocks was much studied but  the  fascia  iliaca compartment block was  less well known at that time.  The study of this block showed safe local anaesthetic plasma concentrations with or without adrenaline and median duration of analgesia of around 10 hours which was not affected by adrenaline. In individual cases much longer  analgesia  was  seen.  The  caudal  study  focussed  on  infants  because  the effect  of  adrenaline  on  plasma  concentration‐time  profiles  of  bupivacaine  had not previously been described. This study confirmed safe plasma concentrations 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of bupivacaine in this young age group and that 1:400,000 adrenaline prolongs the systemic absorption of caudally administered bupivacaine. 
Clinical implications The  addition  of  vasoconstrictors  and  other  analgesic  additives  has  become commonplace  and  the  evidence  of  risks  and  benefits  have  recently  been reviewed  (Ansermino  et  al.,  2003,  de  Beer  and  Thomas,  2003,  APAGBI,  2008, Mazoit and Dalens, 2004).   Bupivacaine  is known to produce more cardiac and central  nervous  system  toxicity  than  the  new  agents  levobupivacaine  and ropivacaine  (Morton,  2004,  Rapp  et  al.,  2004,  Ivani  et  al.,  2002,  Lerman  et  al., 2003, Taylor et al., 2003, Chalkiadis et al., 2004, De Negri et al., 2004, Ivani et al., 2004,  Ivani et al., 1998a,  Ivani et al., 1998b, Da Conceicao et al., 1999, Morton, 2000, Stumpe et al., 2000, Bosenberg et al., 2001, Dalens et al., 2001, De Negri et al., 2001a, De Negri et al., 2001b) and despite many years of safe clinical use in infants and children based on clinical studies and pharmacokinetic studies, many clinicians  have  changed  their  practice  to  adopt  the  new  agents  for  single injection  blocks  and  infusion  techniques.    It  is  hard  not  to  agree  with  this,  in particular  when  there  is  hardly  any  cost  differential  and  the  new  agents  are widely  available.  In  infants  and  in particular neonates, where  local  anaesthetic toxicity is a real risk, the new agents have superceded bupivacaine. 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4.1 Patient­controlled analgesia in children 
4.1.1  Irwin M, Gillespie  JA, Morton NS. Evaluation of a disposable patient­
controlled  analgesia  device  in  children.[see  comment].  British  Journal  of 
Anaesthesia. 1992 Apr;68(4):411­3. 
Abstract 
A  disposable  patient­controlled  analgesia  (PCA)  device  was  evaluated  in  20 
children  after major  abdominal,  urological  and  orthopaedic  surgery.  All  patients 
were given a high dependency level of nursing care in general wards. Efficacy (as 
assessed  by  hourly  pain  scores)  was  comparable  to  that  achieved  in  a  matched 
control  group  of  20  children  who  used  the  Graseby  PCA  system.  Safety  was 
confirmed  by  monitoring  arterial  oxygen  saturation,  sedation  scores  and 
ventilatory frequency. Morphine consumption was similar with the two techniques, 
but  varied widely  between  patients.  The  disposable  device  has  a  complementary 
role to play in the provision of a comprehensive pain relief service for children. 
  
Discussion At the time this study was published, PCA was not well established in paediatrics. It  was  unusual  at  that  time  for  opioid  infusion  techniques  to  be  managed  in general  postoperative  wards  and  so  continuing  pain  control  beyond  the  early postoperative period was problematic. A few descriptions of PCA in children had been  published  (Rodgers  et  al.,  1988,  Schechter  et  al.,  1988,  Gaukroger  et  al., 1989, Webb et al., 1989, Tyler, 1990, Berde et al., 1991, Gaukroger et al., 1991, Mackie et al., 1991) but there was a wide variation in regimens and the optimum regimen  had  yet  to  be  defined.  This  study  of  a  disposable  device was  the  first 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description  of  its  use  in  children  and  proved  as  effective  as  a  conventional electronic  PCA  pump  (Irwin  et  al.,  1992).    The  department  in  Glasgow  at  this time  completed  a  portfolio  of  studies  on  PCA  in  children  to  try  to  define  the optimum  regimen  for  PCA  in  children,  the  limits  of  its  application  and  the monitoring  standards  for  safe  use  in  general ward  environments  (Doyle  et  al., 1993b, Doyle et al., 1993d, Doyle et al., 1994a, Doyle et al., 1994b, Doyle et al., 1994c, Morton and O'Brien, 1999, Munro et al., 2002). From these studies, most of which comprised an MD Thesis for Dr E Doyle, the efficacy and safety of PCA in children  from  age  5  years  of  age  upwards  was  established  and  subsequently confirmed  by  many  other  studies  (Shapiro  et  al.,  1993,  Weldon  et  al.,  1993, Dunbar  et  al.,  1995,  Collins  et  al.,  1996, Hansen  et  al.,  1996,  Tyler  et  al.,  1996, Kanagasundaram et al., 1997, McNeely and Trentadue, 1997, Petrat et al., 1997, Trentadue et al., 1998, Peters et al., 1999, Sutters et al., 1999, Kotzer and Foster, 2000,  Lambert  and  Mayor,  2000,  Bozkurt,  2002,  Dix  et  al.,  2003,  Jacob  et  al., 2003, Ozalevli et al., 2005, Kelly et al., 2006). 
Clinical implications PCA is now widely used in children and has a strong body of evidence supporting its  safety  and  effectiveness  (ANZCA,  2005,  APAGBI,  2008).  New  features highlighted  by  the  Glasgow  studies  were  the  usefulness  of  a  low‐dose background infusion in improving sleep patterns, clarification of the monitoring requirements for safe use in general wards, the optimum regimen for paediatric PCA (20 micrograms/kg bolus, 5 minute lockout interval, 4‐5 micrograms/kg/h background infusion), the possibilities for anti‐emetic treatment, the fact that the Subcutaneous route for PCA worked in children and the usefulness of disposable PCA devices in children. 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4.1  Morphine­sparing  effect  of  NSAIDs  and  paracetamol  in 
children 
4.1.1  Morton  NS,  O'Brien  K.  Analgesic  efficacy  of  paracetamol  and 
diclofenac  in  children  receiving  PCA  morphine.  British  Journal  of 
Anaesthesia. 1999 May;82(5):715­7.  
Abstract 
We  studied  80  children,  aged  5­13  yr,  who  received  PCA  with  morphine  after 
appendicectomy  using  a  standardized  tracheal  general  anaesthetic.  All  patients 
received  morphine  0.1  mg/kg  before  surgical  incision  and  all  had  wound 
infiltration  with  bupivacaine  1  mg/kg  at  the  end  of  surgery.  Patients  were 
allocated  randomly  to  receive postoperative analgesia with PCA morphine alone, 
morphine  plus  diclofenac  1 mg/kg,  morphine  plus  paracetamol  15­20 mg/kg  or 
morphine  plus  a  combination  of  both  diclofenac  and  paracetamol.  Cumulative 
morphine consumption was significantly reduced by concurrent administration of 
diclofenac but no additive effect of paracetamol was demonstrable with the doses 
used  in  the  study.  Analgesia,  as  assessed  by  movement  pain  scoring,  was 
significantly  improved  by  the  addition  of  diclofenac  despite  lower  morphine 
consumption.  Adverse  effects  and  duration  of  PCA  were  comparable  in  the  four 
groups. 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Discussion NSAIDs  and  paracetamol  are  now  well  established  in  paediatric  practice (Sweetman,  2007,  RCA,  1998,  ANZCA,  2005,  APAGBI,  2008,  BNFc,  2008).    The concept  of  concurrent  administration  of  analgesics  from  different  classes  was not accepted in paediatrics at this time however and this study was designed to demonstrate the effectiveness of co‐analgesia (Morton and O'Brien, 1999).   The results  showed  that  diclofenac  produced  a  40%  morphine‐sparing  effect  and better  analgesia  while  paracetamol  produced  approximately  20%  morphine‐sparing. The dose of paracetamol used in this study was low however and recent advice suggests larger doses should be used (Anderson and Palmer, 2006).   
Clinical implications Multimodal  co‐analgesia  is  now  routinely used  and advised  for paediatric pain control  (APAGBI,  2008,  Walker  et  al.,  2006,  ANZCA,  2005).  The  methodology used in this study may be useful in objectively evaluating new NSAIDs and new formulations, such as intravenous paracetamol, in children. 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4.2 Pharmacokinetics of paracetamol in children 
4.2.1 Hansen TG, O'Brien K, Morton NS, Rasmussen SN. Plasma paracetamol 
concentrations  and  pharmacokinetics  following  rectal  administration  in 
neonates  and  young  infants.  Acta  Anaesthesiologica  Scandinavica.  1999 
Sep;43(8):855­9.  
Abstract 
BACKGROUND:  Despite  widespread  use  in  children  pharmacokinetic  data  about 
paracetamol  are  relatively  scarce,  not  the  least  in  the  youngest  age  groups.  This 
study aimed to describe plasma paracetamol concentrations and pharmacokinetics 
of  a  single  rectal  paracetamol  dose  in  neonates  and  young  infants.  METHODS: 
Perioperatively, 17 neonates and infants < or =160 days of age received one rectal 
paracetamol dose (mean 23.9 mg/kg (+/­4.2 mg/kg)). Blood samples were drawn 
at 60, 120, 180, 240, 300 and 360 min, according  to  the  infants' weights. Plasma 
paracetamol  concentrations  were  measured  by  a  Colorometric  Assay,  Ectachem 
Clinical  Chemistry  Slides  (Johnson &  Johnson Clinical Diagnostics). RESULTS: The 
plasma  paracetamol  concentrations  were  mainly  below  the  therapeutic  (i.e. 
antipyretic) range of 66­132 micromol/l and did not exceed 160 micromol/l in any 
infant.  The  mean  maximum  plasma  concentration  (Cmax)  was  72.4  micromol/l 
(+/­33.5  micromol/l)  and  the  time  to  Cmax,  i.e.  the  mean  Tmax  was  102.4  min 
(_+59.1 min).  The mean  "apparent"  terminal  half­life  (n=10) was  243.6 min  (+/­
114.1 min). CONCLUSION: The absorption of rectal paracetamol (mean dose 23.9 
mg/kg, +/­4.2mg/kg)  in young  infants <160 days  is variable and often prolonged 
and achieves mainly subtherapeutic plasma concentrations. 
Discussion This study demonstrated the poor bioavailability of suppository formulations of paracetamol  in  neonates,  infants  and  children,  which  is  now  well  established (Anderson,  1998,  Anderson  and  Holford,  2008).  This  study  was  incorporated into a pooled analysis of paracetamol pharmacokinetics in infants which helped rationalise dosing regimens (Anderson, 1998, Anderson and Palmer, 2006). 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CHAPTER 6:  
 
IMPROVING STRESS 
CONTROL IN CHILDREN 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6.1  Reducing  the  stress  response  to  open  heart  surgery  in 
children 
 6.1.1 Laycock GJ, Mitchell  IM, Paton RD, Donaghey SF, Logan RW, Morton 
NS.  EEG burst  suppression with propofol  during  cardiopulmonary bypass 
in children: a study of the haemodynamic, metabolic and endocrine effects. 
British Journal of Anaesthesia. 1992 Oct;69(4):356­62.  
Abstract 
We  have  studied  the  effects  of  propofol,  given  to  maintain  EEG  suppression 
throughout  cardiopulmonary  bypass  (CPB),  in  20  children  aged  1­15  yr,  in  a 
parallel group comparison. Anaesthesia was produced by fentanyl 50 micrograms 
/kg, enflurane or halothane and midazolam 0.1 mg /kg at  the start of CPB. After 
randomization, 50% of the children also received propofol during CPB. All children 
were cooled during CPB (25­28 degrees C) and pump flows (non­pulsatile) were 2.4 
litre  min­1  m­2,  reducing  to  1.2­1.6  litre  min­1  m­2  during  hypothermia.  Large 
rates  of  infusion  of  propofol  were  required  to  maintain  EEG  suppression, 
particularly during rewarming. Compared with control, the propofol group showed 
significant increases in mixed venous oxygen saturation and significant reductions 
in systemic oxygen uptake and glucose and cortisol concentrations. There were no 
differences in triiodothyronine and lactate concentrations, mean arterial pressure 
during CPB and inotrope requirement after CPB, or in recovery times.   
6.1.2  Bell  G,  Dickson  U,  Arana  A,  Robinson  D,  Marshall  C,  Morton  N. 
Remifentanil  vs  fentanyl/morphine  for  pain  and  stress  control  during 
pediatric cardiac surgery. Paediatric Anaesthesia. 2004 Oct;14(10):856­60.  
Abstract 
BACKGROUND: Remifentanil is a short acting, potent synthetic opioid that does not 
accumulate after infusion or repeated bolus doses. It may be rapidly titrated to the 
requirements of  individual patients. Titrated  infusion of remifentanil may be able 
to provide potent analgesia required for pediatric cardiac surgery and obtund the 
stress  response  in  theater whilst not having  the persistent  respiratory depression 
and  sedation  seen  with  longer  acting  opioids.  METHODS:  Twenty  patients  were 
randomized  to  receive  a  titrated  infusion  of  remifentanil  (0­1 microg  x  kg(­1)  x 
min(­1))  or  a  standard  dose  of  fentanyl  (30  microg  x  kg(­1))  prebypass  plus 
morphine  (1 mg  x  kg(­1))  on  rewarming.  Blood  samples  for  glucose  and  cortisol 
were taken at regular intervals from induction through bypass and into the first 24 
h of postoperative intensive care. In addition to biochemical indicators of the stress 
response  we  recorded  baseline  hemodynamic  parameters  and  any  acute 
physiological  events.  RESULTS:  Ten  patients  received  morphine,  seven  received 
remifentanil.  There  were  no  statistically  significant  differences  between  the  two 
treatment groups  in cortisol measurements, mean arterial pressure or heart  rate 
recordings. In the last time period the remifentanil group had a larger rise in blood 
glucose  concentration  (baseline  3.9,  rise  3  mmol  x  l(­1))  than  the 
fentanyl/morphine  group  (baseline  4.2  rise  1.9  mmol  x  l(­1)),  CI  ­4.3  to  ­0.2. 
CONCLUSIONS:  The  only  significant  difference  was  in  glucose  in  the  postbypass 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time  periods.  Although  statistically  significant,  this  difference  is  insufficient 
evidence of increased stress in the remifentanil group. The results show that in the 
patients  studied  there  was  no  clinically  important  difference  between  the  two 
techniques. 
Discussion The  stress  response  to  surgery  in  children  has  been  of  great  interest  since Anand’s  early  studies  30  years  ago  highlighted  stress  control  as  an  issue  for neonates,  infants  and  children  undergoing  major  surgery  (Anand  et  al.,  1987, Anand  and  Aynsley‐Green,  1988,  Anand  et  al.,  1988,  Anand  and  Carr,  1989, Anand et al., 1990). Regional  analgesia techniques (Wolf, 1993, Wolf et al., 1993, Wolf  et  al.,  1998)  and a  variety of  opioids  (Bouwmeester  et  al.,  2001, Bozkurt, 2002, van Dijk et al., 2002, Bozkurt et al., 2003, Bozkurt et al., 2004, Humphreys et al., 2004)have been studied in detail. Our first study of propofol was unusual in  using  deep  intravenous  anaesthesia  to manage  the  stress  response  to  open heart  surgery  and  cardiopulmonary  bypass  (Laycock  et  al.,  1992).  With  more sophisticated depth of anaesthesia monitors now available such as BIS and AEP, this  technique  can  be  adapted  to modern  practice  and  indeed  this  is  now my normal  technique  for  most  paediatric  cardiac  anaesthesia,  using  TCI  propofol and alfentanil with AEP monitoring. The second study used the new ultra‐short‐acting opioid remifentanil  to achieve stress control  in a small study (Bell et al., 2004).  A  number  of  others  have  investigated  remifentanil  in  neonates,  infants and children (Davis et al., 1999, Hammer et al., 2005, Welzing and Roth, 2006) although there are concerns about acute tolerance (Crawford et al., 2006). 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6.2 Stress free tracheal intubation in children without the use of 
muscle relaxants  
6.2.1  Steyn  MP,  Quinn  AM,  Gillespie  JA,  Miller  DC,  Best  CJ,  Morton  NS. 
Tracheal  intubation  without  neuromuscular  block  in  children.[see 
comment]. British Journal of Anaesthesia. 1994 Apr;72(4):403­6.  
Abstract 
We have studied 80 healthy children, aged 2­14 yr, undergoing adenotonsillectomy 
in  a  double­blind,  randomized  design.  Tracheal  intubation  facilitated  by  either 
suxamethonium 1.5 mg /kg or alfentanil 15 micrograms /kg was compared after 
induction  of  anaesthesia  with  propofol  3­4  mg  /kg.  The  quality  of  tracheal 
intubation was graded according to the ease of laryngoscopy, position of the vocal 
cords, coughing, jaw relaxation and movement of limbs. There were no significant 
differences  in  the  overall  assessment  of  intubating  conditions  between  the  two 
groups, and all children underwent successful tracheal  intubation. Fewer patients 
coughed  (P  <  0.014)  and  limb  movement  was  less  common  (P  <  0.007)  after 
tracheal  intubation  facilitated  by  suxamethonium.  Alfentanil  attenuated  the 
haemodynamic responses to tracheal intubation. 
6.2.2  Robinson  DN,  O'Brien  K,  Kumar  R,  Morton  NS.  Tracheal  intubation 
without  neuromuscular  blockade  in  children:  a  comparison  of  propofol 
combined  either  with  alfentanil  or  remifentanil.  Paediatric  Anaesthesia. 
1998;8(6):467­71.  
Abstract 
Forty healthy children, aged between two and 12 years of age undergoing elective 
surgery where the anaesthetic technique involved tracheal intubation followed by 
spontaneous  ventilation  were  studied.  Induction  of  anaesthesia  was  with  either 
alfentanil  15  micrograms./kg  or  remifentanil  1  microgram./kg  followed  by 
propofol  4  mg./kg  to  which  lignocaine  0.2  mg./kg  had  been  added.  Intubating 
conditions were graded on a  four point scale  for ease of  laryngoscopy, vocal cord 
position, degree of coughing, jaw relaxation and limb movement. All children were 
successfully intubated at the first attempt. There were no significant differences in 
the  assessments  of  intubating  conditions  between  the  two  groups.  Arterial  blood 
pressure  and  heart  changes were  similar  in  the  two  groups with  both  alfentanil 
and remifentanil attenuating  the haemodynamic response  to  tracheal  intubation. 
The  time  taken  to  resumption  of  spontaneous  ventilation  was  similar  in  both 
groups. 
Discussion These studies were among the first to explore intubation without muscle relaxants in children using propofol and short acting opioids (Robinson et al., 1998, Steyn et al., 1994).  Around this time, we also conducted a study comparing 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the then relatively new agent sevoflurane with halothane for tracheal intubation (O'Brien et al., 1998). All the studies focussed primarily on the quality of intubating conditions and the speed of achieving satisfactory conditions. With the opioid/ propofol techniques it was clear that the stress response related haemodynamic effects of tracheal intubation were also ameliorated significantly. 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& 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Advice  to  clinicians  on  assessment  and management  of  pain  has  been  brought together  in a number of guidelines  in  the  last 10 years (RCN, 1999, RCA, 1998, ANZCA, 2005, APAGBI, 2008, Playfor et al., 2006, SIGN, 2004).  These guidelines cover  best  practice  in  procedural  analgesia,  postoperative  analgesia,  pain assessment, and sedation and analgesia in paediatric intensive care.   Aspects of the  implementation of  these guidelines has been audited  in  two major projects covering epidural infusion analgesia (Llewellyn and Moriarty, 2007) in children and opioid infusion techniques in children (Morton, 2008c).  
Audit of epidural infusion analgesia 
This project involved most of the acute paediatric pain teams throughout the UK and  was  designed  to  quantify  the  risks  associated  with  epidural  infusion analgesia  in  children.    Data were  collected  over  five  years.    96  incidents were reported  in 10,633 epidurals. 56  (1:189) were associated with  the  insertion or maintenance  of  the  epidural  and most  were  of  low  severity.  5  incidents  were graded as serious (1:2000). Only one child had residual effects (1:10,000). Four incidents  of  compartment  syndrome  occurred  which  were  not  masked  by  the epidural. The results of this audit project have been used to produce information for  children  and  families  about  the  risks  and  benefits  of  epidural  infusion analgesia.   
Audit of opioid infusion techniques Following the success of the National Epidural Audit project, the APAGBI agreed to  fund  an  analogous  audit  project  for  opioid  infusion  techniques  in  children (continuous  infusions,  patient‐controlled  analgesia  and  nurse‐controlled 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analgesia) (Morton, 2008c). This project is in progress from July 2007‐December 2008  and  the  interim  results  collated  after  6  months  reveal  21  reported incidents  out  of  4273  opioid  infusion  techniques  (1:  200).  9  were  graded  as severe  (1:500)  with  one  child  having  residual  problems  at  discharge  from hospital  (1:4273).  These  serious  cases  were  1  cardio‐respiratory  arrest  in  a neonate, 6 cases of respiratory depression requiring naloxone administration, 2 further cases of respiratory depression requiring bag and mask ventilation and oxygen but no naloxone. A number of less severe opioid‐related adverse effects were  reported  such  as  pruritis,  urinary  retention  and  emesis  were  reported. These were treated either by stopping the morphine or by switching to another opioid.  A  number  of  potential  drug  calculation  and  dilution  errors  were  also reported but all were identified before harm occurred. The audit continues until 10,000  cases  are  registered  and  this  should  allow  comparison  of  the  relative risks of opioid infusion techniques compared with epidural  infusion techniques in  children  in  the  UK which,  in  turn, will  help  inform  families  and  children  in future. 
SIGN GUIDELINE 58:  SAFE SEDATION OF CHILDREN 
UNDERGOING DIAGNOSTIC AND THERAPEUTIC 
PROCEDURES(SIGN, 2004) This evidence‐based guideline was developed by a working group chaired by the author  after  a  Scottish  national  audit  revealed  wide  variation  in  paediatric procedural sedation practice across the country (Morton and Oomen, 1998).  The guidelines  were  accompanied  by  recommendations  for  consent  procedures, monitoring, documentation and case selection (see Appendix 2). Recently, NICE have selected this as a topic for their guidelines programme. 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Glasgow Protocol for Acute Pain Management (See Appendix 3) 
 The  local  acute  pain protocol  used  in Glasgow  is  a  synthesis  of  current  dosing schedules.  This  protocol  has  been  developed  and  evolved  since  1994  and  has proven to be very successful as a basis for education of doctors and nurses and ensures more equity of pain management across our hospital. Monitoring charts for each technique and pain assessment charting  is now routine  in the hospital and is regarded as the 6th vital sign. This protocol has informed an RCPCH book on  pain  management  (RCPCH,  1997)  and  the  analgesia  section  of  the  British National Formulary for Children (BNFc, 2008). 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CHAPTER 8: 
 
CONCLUSIONS 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This thesis describes a range of studies that have contributed to improvements in  pain  management  of  children  over  the  last  20  years.  The  focus  of  most paediatric  anaesthetists  in  the  late  1980’s  was  upon  immediate  anaesthetic management  in  the  operating  theatre,  with  adaptation  of  new  monitoring modalities and general anaesthetic agents to paediatric practice in the interests of safety and  improved outcome, especially as sicker and younger  infants were subjected  to  corrective  surgery.  It  was  realised  that  intraoperative  regional analgesia  and  continuing  pain  control  were  equally  important.  The  studies described in detail, supplemented by a number of others included in co‐worker’s theses, have contributed to the evidence base for clinical practice guidelines and protocols  which  allow  extremely  successful  and  safe  pain  management  of  the vast majority  of  children. These  techniques have been  adopted widely  and  are now  routine  practice  around  the  world  and  can  indeed  be  regarded  as  the standard of care  for children undergoing surgery and diagnostic or  therapeutic procedures. The recent collation of evidence‐based guidance confirms that pain management  of  children  has  improved  (APAGBI,  2008,  BNFc,  2008,  Walker, 2008, ANZCA, 2005). 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ACUTE  PAIN  RELIEF  SERVICE  (APRS)  PROTOCOL  v12.1 
October 2006 
Minimum monitoring standard One  nurse  per  4  patients;  continuous  pulse  oximetry;  hourly  nurse  recordings using  appropriate  monitoring  charts;  twice  daily  visits  by  pain  relief  nurse specialist and/or duty anaesthetists; once daily visit by pain consultant. 
General points Doses are a guide only and should be titrated against monitoring results. The medical condition, surgical condition, age and maturity of the child will affect the regimen. If possible ward medical staff should perform refilling of opioid syringes after appropriate training. Programming or reprogramming of PCA devices or epidural pumps should only be performed by the APRS. Anaesthetic staff only should perform refilling local anaesthetic syringes and epidural top‐ups. Ensure all syringes for opioid or local anaesthetic infusions are correctly labelled. Ensure prescription is correctly and legibly written, signed, dated and timed on the additive label, in the drug Kardex and on the monitoring chart. Ensure the appropriate monitoring chart has all the requested information accurately filled in and accompanies the patient to the ward or PICU.  
Beware! 
Double check: All opioid and local anaesthetic infusions should be checked by 2 practitioners.  Check  drug  dosages,  drug  dilutions,  pump  settings,  concurrent prescription of different opioids, gravity free flow/ siphonage/ reflux of opioids, injection or infusion of the wrong substance into epidurals. 
OPIOIDS 
TITRATION  TO  ANALGESIA  WITH  IV  MORPHINE  [ensure  appropriate 
monitoring and availability of naloxone] 
Pre­term  neonate:  give  increments  of  0.005mg/kg  ie.  5micrograms/kg  at  5 minute intervals up to 0.025mg/kg ie. 25micrograms/kg 
Term neonate: give increments of 0.02mg/kg ie. 20micrograms/kg at 5 minute intervals up to 0.1mg/kg ie. 100micrograms/kg 
Age  1­3m:  give  increments  of  0.02mg/kg  ie.  20micrograms/kg  at  5  minute intervals up to 0.1mg/kg ie. 100micrograms/kg 
>3m: give  increments of 0.05mg/kg  ie. 50micrograms/kg at 5 minute  intervals up to 0.1‐0.2mg/kg ie. 100‐200micrograms/kg 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OPIOID INFUSIONS 
Loading doses Consider loading dose of morphine if >3m old give increments of 0.05mg/kg ie. 50micrograms/kg  at  5  minute  intervals  up  to  0.1‐0.2mg/kg  ie.  100‐200micrograms/kg;  omit  if  <3m  or  has  good  local/  regional  block  or  has received loading dose of morphine or another opioid. 
Intravenous morphine infusion (IVM) Use anti‐free flow valve & dedicated cannula if possible. If morphine infusion has to  be  given  concurrently with  another  infusion  use  anti‐free  flow +  anti‐reflux valves. Morphine 1mg/kg in 50mls 0.9%saline (≡0.02mg/kg/ml ie.20micrograms/kg/ml); maximum 50mg in 50mls 
 
Initial IVM settings for paediatrics Self‐ventilating Age   Pre‐term: up to 0.005mg/kg/h ie. 5micrograms/kg/h ≡ 0.25ml/h Term neonate: up to 0.08mg/kg/h ie.  8micrograms/kg/h ≡ 0.4ml/h           1‐3m: up to 0.010mg/kg/h ie. 10micrograms/kg/h ≡ 0.5ml/h            >3m: up to 0.020mg/kg/h ie. 20micrograms/kg/h ≡ 1ml/h Ventilated in intensive care          Up to 0.040mg/kg/h ie. 40micrograms/kg/h ≡ 2ml/h 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Patient controlled analgesia with morphine (PCAM) Use anti‐free flow valve & dedicated cannula if possible. If morphine infusion has to  be  given  concurrently with  another  infusion  use  anti‐free  flow +  anti‐reflux valves. Morphine 1mg/kg in 50mls 0.9%saline (≡0.02mg/kg/ml ie.20micrograms/kg/ml); maximum 50mg in 50mls (1mg/ml) 
Initial IVPCAM settings (20,5,4) Bolus dose 0.020mg/kg ie. 20micrograms/kg ≡ 1.0ml maximum bolus dose 1mg (for 50kg+) Lockout interval 5 minutes Background  infusion  0.004mg/kg/h  ie.4micrograms/kg/h ≡  0.2ml/h  [useful  in first 24h to improve sleep pattern] Omit if 50kg+ or if has had single shot epidural 
or regional block 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Nurse­controlled analgesia with morphine (NCAM) Use  anti‐free  flow  valve.  Use  dedicated  cannula  where  possible.  If  morphine infusion has to be given concurrently with another infusion use anti‐free flow + antireflux valves. Morphine 1mg/kg in 50mls 0.9%saline (≡0.02mg/kg/ml ie.20micrograms/kg/ml); maximum 50mg in 50mls (1mg/ml) 
  
Initial NCAM settings (20,20,20) Age <1m self‐ventilating Bolus dose 0.005mg/kg ie. 5 micrograms/kg ≡ 0.25ml Lockout interval 30 minutes No background infusion Age 1‐3m self‐ventilating Bolus  dose  0.010mg/kg  ie.  10micrograms/kg  ≡  0.5mlLockout  interval  30 minutes No background infusion Age > 3m self‐ventilating, any age ventilated in intensive care Bolus dose 0.020mg/kg ie. 20micrograms/kg ≡ 1.0ml maximum bolus dose 1mg (for 50kg+) Lockout interval 20 minutes Background infusion 0.020mg/kg/h ie.20micrograms/kg/h ≡ 1ml/h 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CO­ANALGESIA FOR ACUTE PAIN 
Paracetamol dose as per table below; time the doses for the first 48h; caution if 
liver dysfunction, reduce loading dose and increase dosing interval in neonates. 
Oral /rectal route 
 
                Oral 
   
           Rectal 
 
Age  
 
Loading 
dose 
 
Maintenance 
dose 
 
Loading  
Dose 
 
Maintenance 
dose 
Maximum 
daily dose 
(Oral or 
rectal) 
Duration 
at max. 
dose 
Preterm 28‐32w  20mg/kg  15mg/kg up to 12hrly  20mg/kg  15mg/kg up to 12hrly   35mg/kg/day  
 48h 
Preterm 32‐38w  20mg/kg  20mg/kg up to 8hrly  30mg/kg  20mg/kg up to 12hrly     60mg/kg/day   48h 0‐3m  20mg/kg  20mg/kg up to 8hrly  30mg/kg  20mg/kg up to 12hrly        60mg/kg/day   48h >3m  20mg/kg  15mg/kg up to 4hrly  40mg/kg  20mg/kg up to 6hrly     90mg/kg/day   72h 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IV route 
 
                IV 
 
Age  
 
Loading 
dose 
 
Maintenance 
dose 
 
Maximum daily 
dose 
 
 
Duration at max. 
dose 
Preterm 28‐32w  15mg/kg  15mg/kg up to 12hrly  35mg/kg/day   48h Preterm 32‐38w  15mg/kg  15mg/kg up to 8hrly  45mg/kg/day  48h 0‐3m  15mg/kg  15mg/kg up to 8hrly  45mg/kg/day  48h >3m  15mg/kg  15mg/kg up to 6hrly  60mg/kg/day  72h 
 
Diclofenac  Age  6m+:  1mg/kg  up  to  8hourly  o/pr  (max  3mg/kg/day  or 150mg/day whichever is less) [time doses for first 48h]. Caution if bleeding risk, 
asthma, atopy, renal dysfunction, GI ulceration/ bleeding, on anticoagulants, avoid 
if <6m. 
Ibuprofen Age 1­3m: 5mg/kg up to 6 hourly oral; age 3m+: 10mg/kg up to 8 hourly oral  (max. 30mg/kg/day or 2.4g/day whichever  is  less)  [time doses  for first 48h]. Caution if bleeding risk, asthma, atopy, renal dysfunction, GI ulceration/ 
bleeding, on anticoagulants, avoid if <1m. 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WEANING FROM COMPLEX ANALGESIA Ensure  adequate  doses  of  co‐analgesics  are  prescribed  and  are  being  given  to achieve  morphine‐sparing  effect;  wean  down  infusion  rate  depending  on monitoring results; liaise with surgical colleagues about oral intake, rectal route for  drugs, mobilisation,  dressings,  drain/catheter  removal.  If  prolonged  opioid use (>5 days) wean slowly (20% per day) to avoid withdrawal syndrome.  For  specific  cases  consider  step  across  analgesia  with  oro‐morph  0.3  mg/kg orally  or  dihydrocodeine,  0.5‐1mg/kg  orally  6hourly  and  ensure  parenteral morphine has been stopped (avoid concurrent prescription of opioids). 
ANTAGONISTS 
Use Basic Life Support measures (ABC); give oxygen 
For opioid antagonism: Naloxone 2‐10micrograms/kg iv stat; can be repeated every 60 seconds or  start  infusion at 10micrograms/kg/h; use  lowest effective dose; if no venous access give IM 100micrograms/kg 
For  benzodiazepine  antagonism:  Flumazenil  5micrograms/kg  iv  stat;  can  be repeated every 60 seconds or start infusion at 10micrograms/kg/h 
Beware seizures precipitated by antagonists. 
ANTIEMETICS  Ondansetron 0.1mg/kg (100micrograms/kg) iv or oral; trimeprazine 0.25mg/kg (250micrograms/kg) oral; cyclizine 1mg/kg iv or oral  
MUSCLE  SPASMS  IN  ORTHOPAEDICS/  BLADDER  SPASMS  IN  UROLOGY Diazepam 0.1mg/kg (100micrograms/kg) 6hourly oral  Midazolam infusion 0.025mg/kg/h (25micrograms/kg/h) iv (ie. ¼ of the sedative 
dose) [ensure appropriate monitoring]. 
DRESSINGS & DRAIN REMOVALS Consider Entonox (use Entonox protocol), opioid bolus, epidural top up. [ensure appropriate monitoring] 
SKIN GRAFT DONOR SITES Lyofoam  dressing  soaked  with  2mg/kg  levobupivacaine,  2.5mg/ml  (0.25%)  plain/1:200,000 adrenaline; put epidural catheter on dressing surface and infuse levobupivacaine,  2.5mg/ml  (0.25%)  at  0.1‐0.2ml/kg/h  ≡  0.25‐0.5mg/kg/h  ≡ 250‐500micrograms/kg/h; use wound perfusion monitoring chart. 
 
BONE GRAFT DONOR SITES Wound perfusion with levobupivacaine, 2.5mg/ml (0.25%) plain @ 0.1ml/kg/h 
≡ 0.25mg/kg/h ≡ 250micrograms/kg/h; use wound perfusion monitoring chart 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EPIDURAL LEVOBUPIVACAINE (PLAIN SOLUTIONS) 
In theatre 
<8y  levobupivacaine,  2.5mg/ml  (0.25%) 0.25% up  to  1.0ml/kg  in  fractionated doses (may need 50% less for thoracic epidural) 
8y+ levobupivacaine, 5mg/ml (0.5%) up to 0.5ml/kg in fractionated doses (may need 50% less for thoracic epidural) 
If  <6m  use  IV  route  for  rescue  analgesia  and  following  instructions  above  for titration to analgesia with IV morphine. 
If  6m+  place  SC  cannula  for  rescue  analgesia  and  prescribe  0.1mg/kg (100micrograms/kg) sc morphine which can be given by ward nursing staff   or ward doctor. If no sc cannula, iv morphine up to 0.1mg/kg (100micrograms/kg) can  be  given  by  ward  doctor,  anaesthetist  or  certificated  nurse  following instructions above for titration to analgesia with IV morphine. 
 
In recovery Check block, check adequacy of analgesia, check adequacy of sedation, check for restlessness. Top  up  if  required  with    levobupivacaine,  2.5mg/ml  (0.25%),  3.75mg/ml (0.375%) or 5mg/ml (0.5%) as appropriate. If restless, follow instructions above for titration to analgesia with IV morphine. If epidural is not working after top ups and partial withdrawal of catheter, take it out and change to another form of analgesia. 
 
Postoperative  
Infusion regimen 
Age <6m  Levobupivacaine infusion, 1.25mg/ml (0.125%) plain @ 0.1‐0.2ml/kg/h ≡ 0.125‐0.25mg/kg/h ≡ 125‐250micrograms/kg/h May  need  top  ups  levobupivacaine,  2.5mg/ml  (0.25%)  0.1‐0.3ml/kg  ≡  0.25‐0.75mg/kg ≡ 250‐750micrograms/kg in fractionated doses [maximum total dose (including top ups) per 4h period 1.0mg/kg] 
Check  block;  give  top  up  in  fractionated  doses;  check  BP,HR,RR,SpO2  every  5 
minutes  for  15 minutes;  recheck  block  and  pain  score.  Aim  for  differential  block 
with preservation of motor power and good analgesia.  If block  is very dense with 
profound motor blockade, consult senior for review. 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Age 6m+  Levobupivacaine infusion, 1.25mg/ml (0.125%) plain @ 0.2‐0.4ml/kg/h ≡ 0.25‐0.5mg/kg/h ≡ 250‐500micrograms/kg/h May  need  top  ups  levobupivacaine,  2.5mg/ml  (0.25%)  0.1‐0.3ml/kg  ≡  0.25‐0.75mg/kg ≡ 250‐750micrograms/kg in fractionated doses [maximum total dose (including top ups) per 4h period 2.0mg/kg] 
Check  block;  give  top  up  in  fractionated  doses;  check  BP,HR,RR,SpO2  every  5 
minutes  for  15 minutes;  recheck  block  and  pain  score.  Aim  for  differential  block 
with preservation of motor power and good analgesia.  If block  is very dense with 
profound motor blockade, consult senior for review. 
RESCUE ANALGESIA 
If  <6m  use  IV  route  for  rescue  analgesia  and  following  instructions  above  for titration to analgesia with IV morphine. 
If  6m+  place  SC  cannula  for  rescue  analgesia  and  prescribe  0.1mg/kg (100micrograms/kg) sc morphine which can be given by ward nursing staff   or ward doctor. If no sc cannula, iv morphine up to 0.1mg/kg (100micrograms/kg) can  be  given  by  ward  doctor,  anaesthetist  or  certificated  nurse  following instructions above for titration to analgesia with IV morphine. 
ADDITIVES TO EPIDURAL SOLUTIONS In specific cases, an additive may be mixed with levobupivacaine to prolong the analgesia from a single dose or to increase the dermatomal coverage of the block. These should only be undertaken by anaesthetists and if a trainee, discuss with your consultant and the pain team. Fentanyl 1‐2micrograms /ml of epidural infusion solution Diamorphine 50 micrograms/kg loading dose, then solution of diamorphine, 50 microgram/ml  in  levobupivacaine,  1.25mg/ml  (0.125%)  @  0.1ml/kg/h max. [avoid if age <1y; do not increase infusion rate; top up with plain levobupivacaine; 
for pruritis use  low dose naloxone 0.5micrograms/kg,  repeated every1­2 minutes 
until symptoms resolve then give this total dose hourly as a continuous infusion] Clonidine 1 microgram/kg added to single injection blocks Preservative free racemic ketamine (Curomed) 0.5mg/kg or S (+) ketamine 0.25‐0.5mg/kg added to single injection epidural blocks [S(+)ketamine has twice the analgesic potency of racemic ketamine] 
DRUGS USED IN MANAGEMENT OF EXCESSIVELY HIGH BLOCK 
Use Basic Life Support measures (ABC); give oxygen; give iv fluids; call duty 
anaesthetist Ephedrine 0.1‐1 mg/kg IV; Atropine 10‐20 micrograms/kg IV or IM 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An evaluation of a new self-adhesive patch preparation of amethocaine 
for topical anaesthesia prior to venous cannulation in children 
E. DOYLE, J.  FREEMAN, N. T. IM AND N. S. MORTON 
Summary 
A new preparation of amethocaine in the form of a sey-adhesive patch, designed to provide topical cutaneous anaesthesia prior to 
venous cannulation. was evaluated in an open study of 189 children. The new preparation of amethocaine was in place for a mean 
time of 48 min ( S D  3.9). Eighty percent of patients had a satisfactory degree of analgesia for  venous cannulation. Nine percent 
of patients experienced moderate pain and I I % experienced severe pain during venous cannulation. In 26% of patients there was 
slight (24%) or moderate (2%) erythema at the site of application, and in 5% slight oedema was noted at the site of application. 
Eight percent of patients had slight itching and I %  had moderate itching at the site of application. There was a clinical 
impression that venous dilatation made cannulation easier than with EMLA cream. These results suggest that this convenient 
preparation of amethocaine is highly effective at providing adequate topical cutaneous anaesthesia with a short onset time and a 
low incidence of minor side effects with no evidence of systemic toxicity. 
Key words 
Anaesthetic techniques, regional; topical. 
Veins; venipuncture. 
Anaesthefics. local; amethocaine. 
The provision of cutaneous topical anaesthesia prior to 
venepuncture or venous cannulation is clearly desirable. 
This is particularly so in paediatric practice when pain can 
make these procedures stressful for both doctor and 
patient. The only effective topical anaesthetic preparation 
currently available is a eutectic mixture of lignocaine and 
prilocaine (EMLA, Astra) and the efficacy of this prepara- 
tion has been well demonstrated [I-61. 
EMLA requires a minimum application time of 1 h 
under an occlusive dressing [7,8], but its anaesthetic effect 
is short, with a duration of 30-60 min [1,7]. There are 
pharmacological and experimental grounds for considering 
amethocaine to be a more appropriate local anaesthetic 
drug to use as a topical preparation than lignocaine or 
prilocaine [9, lo]. 
This paper presents an open study of the efficacy, safety 
and side effects of a new preparation of amethocaine in the 
form of a self-adhesive patch applied topically prior to 
venous cannulation in children. This study was performed 
as an open evaluation rather than as a comparative trial 
against EMLA because it formed part of the phase I1 
evaluation of the preparation for licensing purposes. 
Methods 
The study was approved by the ethics committee of the 
hospital. Informed written parental consent was obtained 
for 189 children aged between 1 and 15 years presenting for 
day case surgery. Exclusion criteria included lack of 
parental consent, weight less than 10 kg, the presence of 
broken skin at the site of application, known sensitivity to 
local anaesthetics and the use of analgesics within the 
preceding 24 h. All children were unpremedicated. 
The weight, height, heart rate and blood pressure of each 
patient were recorded before drug administration. A new 
preparation of amethocaine in the form of a self-adhesive 
patch (Smith & Nephew Pharmaceuticals Ltd), incor- 
porating a thin film of anhydrous amethocaine base 15 mg, 
was applied to the dorsum of one hand over a vein. The 
patch size was 10 cm x 6 cm and the area of drug/skin 
contact was 4.5 cm x 3 cm (13.5 cm’). The specified 
application time was between 45 min and 1 h. Blood 
pressure and heart rate were recorded on removal of the 
amethocaine preparation and any change from the first 
measurement was noted. 
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The patient or parent was asked about itching at  the site 
of application and the site was inspected by the investigator 
for erythema and oedema. Each was graded as absent, 
slight or moderate. These assessments were performed by 
three of the investigators (E.D., J.F. and N.T.I.). 
Venous cannulation was then performed using a 22- or 
24-gauge cannula. The gauge of cannula used depended on 
the size of the vein to be cannulated and the expected ease 
of cannulation. An assessment of pain during cannulation 
was made and scored on a four-point behavioural scale 
previously validated in paediatric studies of injection pain 
due to propofol [ I  I]: 0 = no pain (no grimace, crying or 
withdrawal of the arm); 1 = mild pain (grimace); 2 = 
moderate pain (grimace and cry); 3 = severe pain 
(grimace, cry and withdrawal of the arm). 
A record was kept of all materials applied to the skin. 
Each subject was visited prior to discharge and the site of 
the amethocaine application inspected. The child’s general 
practitioner was informed of his/her patient’s participation 
in the study and asked to report any undue late problems. 
Results 
There were 189 applications of the test patch. Of these, 18 
were invalidated because of violations of the protocol. 
Results from 127 males and 44 females with a mean age of 
73.8 months (SD 35.3) and a mean weight of 23.4 kg (SD 
10.7) were analysed. 
The amethocaine patches were applied for a mean (SD) 
time of 48 (3.9) min. The mean (SD) time between applica- 
tion and cannulation was 59 (27) min. Fifty-six percent of 
children experienced no pain and 24% experienced mild 
pain on venous cannulation (Table I).  Nine percent of 
children experienced moderate and 1 1 % experienced severe 
pain during cannulation. 
At the site of amethocaine application there was mild 
erythema in 24% of patients and moderate erythema in 
2%. Slight oedema was present in 5% of patients. Mild 
itching was noted in 8% of patients and moderate itching 
in 1 %. No clinically significant haemodynamic changes 
were noted and there was no idiosyncratic reactions to the 
amethocaine. 
Discussion 
Our results indicate that after application times of between 
45 min and 1 h this preparation of amethocaine will 
produce satisfactory topical cutaneous anaesthesia, that is, 
no reaction to cannulation or a grimace only, in 80% of 
children undergoing venous cannulation. The preparation 
may in fact have a higher success rate than this because a 
number of children who were scored as having severe pain 
Table 1. Pain during venous cannulation, degree of erythema, 
oedema and itch at site of amethocaine application. 
Pain None Mild Moderate Severe Total 
96 (56%) 41 (24%) 15 (9%) 19 (11%) 171 
127 (74%) 40 (24%) 4 (2%) 171 
163 (95%) 8 (5%) 0 171 
I56 (91%) 13 (8%) 2 (1%) 171 
Erythema Absent Slight Moderate 
Oedema Absent Slight Moderate 
Itch Absent Slight Moderate 
during venous cannulation (cry, grimace and withdrawal of 
the arm) were distressed prior to  cannulation, presumably 
as  a response to  hunger or anxiety. These children may well 
have cried or struggled because of this rather than as a 
consequence of pain. This is a better result than was 
obtained in the early trials of EMLA [I-61. There was a 
preponderance of boys in the study because paediatric day 
case surgery includes a high proportion of procedures such 
as  circumcision and orchidopexy that are only performed 
on boys. 
A short application time may be of benefit in busy wards 
or  outpatient areas where prolonged application times 
disrupt the smooth running of operating lists and clinics. 
The known vasodilator effect of amethocaine [12,13] may 
produce venous dilatation and easier conditions for vene- 
puncture than the vasoconstrictor effect that is occasionally 
seen with EMLA cream. Topical amethocaine appears to  
have a prolonged duration of action [I] persisting after the 
patch is removed. This may prove a useful feature in a busy 
setting where all the patches required for an operating 
session could be applied a t  the same time and removed at  
the same time. There is also the potential for prolonged 
wound analgesia in certain procedures such as skin grafting 
and the removal of minor skin blemishes. 
A suitable preparation of a local anaesthetic drug for 
cutaneous use should provide rapid, effective and relatively 
long lasting anaesthesia of both the skin surface and the 
underlying tissues. It should also contain the minimum 
effective dose of drug. 
The stratum corneum is the main barrier to the absorp- 
tion of drugs through the skin [14]. A lipophilic local 
anaesthetic preparation such as  the base of amethocaine 
should penetrate the lipid-rich barrier of the stratum 
corneum and block the underlying nerve fibres more 
readily than relatively hydrophilic preparations such as the 
salts of lignocaine and prilocaine which constitute EMLA 
cream. 
There is experimental evidence to support the superiority 
of amethocaine over other local anaesthetics for the provi- 
sion of topical cutaneous anaesthesia. When equimolar 
doses of amethocaine and lignocaine in the same formula- 
tion are applied to  volunteers for 30 min, amethocaine 
provides a more significant percutaneous effect [9]. A com- 
parison of equal doses of amethocaine and EMLA in 
volunteers demonstrated that the amethocaine preparation 
produced more rapid onset and increased duration of effect 
when application times of 30 and 60 min were used [I]. 
The greater lipophilicity and potency of amethocaine 
compared with lignocaine and prilocaine, and its greater 
affinity for neural tissue, mean that only a small amount 
need be present in the region of the nerve fibres to exert a 
phamacological action. A relatively long time after removal 
of the drug would be required to reduce the concentration 
of amethocaine present a t  the nerve fibres to less than that 
required for an anaesthetic effect. The affinity of the ameth- 
ocaine molecule for the stratum corneum may result in a 
depot effect by which the drug remains in the skin after 
removal of the application and continues to diffuse through 
the stratum corneum into the dermis. 
The use of a n  ester type local anaesthetic may cause 
concern about possible systemic toxicity especially since a 
highly lipophilic agent such as amethocaine base will 
undergo rapid systemic uptake. However, since ametho- 
caine is an ester, it is subject to  rapid metabolism by 
1052 E.  Doyle et al. 
esterases in the skin and in the blood. Thus, blood concen- 
trations are very low [I 51 and dose-related systemic toxicity 
is unlikely. Esters are more likely than amides to produce 
idiosyncratic toxic effects [16] and a large series of patients 
will be required to  determine the incidence and severity of 
these. 
There was an incidence of slight (24%) or moderate (2%) 
cutaneous erythema at the site of application due to  the 
vasodilator effect of amethocaine. This may aid identifica- 
tion of the application site and make venous cannulation 
easier. Other side effects of the application were infrequent 
and minor and no systemic toxicity was observed. 
These results are encouraging and suggest that this pre- 
paration of amethocaine has a useful rBle in the provision 
of topical cutaneous anaesthesia prior to  venous cannula- 
tion or venepuncture. A controlled, randomised and blind 
comparison with EMLA cream would be of value. 
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Plasma bupivacaine levels after fascia iliaca
compartment block with and without adrenaline
E. DOYLE FRCA, N.S. MORTON FRCA AND L.R. McNICOL FRCA
Department of Anaesthesia, Royal Hospital for Sick Children, Yorkhill, Glasgow G3 8SJ,
Scotland, UK
Summary
Twenty children undergoing unilateral surgery on the thigh received
a fascia iliaca compartment block using 2 mg·kg−1 of bupivacaine
with (Group A) or without (Group P) adrenaline 1/200 000. Venous
blood samples were taken as 5, 10, 15, 20, 25, 30, 40, 50 and 60 min
after injection and assayed for concentrations of bupivacaine. In all
subjects an adequate block was produced. Plasma concentrations of
bupivacaine in Group P were significantly higher than those in
Group A (P<0.05). The median maximum plasma concentration
(Cmax) was 1.1 lg·ml−1 (range 0.54–1.29 lg·ml−1) in Group P and
0.35 lg·ml−1 (range 0.17–0.96 lg·ml−1) in Group A. The median time
taken to attain Cmax (Tmax) was 20 min (range 10–25 min) in Group P
and 45 min (range 5–50 min) in Group A. The median time to first
analgesia was 9.75 h (range 3–15 h) in Group P and 10.5 h (range
2.5–21 h) in Group A. The study confirmed the efficacy of the fascia
iliaca compartment block in children and showed that when
performed with 2 mg·kg−1 of bupivacaine it is associated with
plasma concentrations of bupivacaine well within acceptable limits.
The addition of adrenaline 1/200 000 to the local anaesthetic
solution reduces the maximum plasma concentration reached.
Keywords: paediatric; analgesia; fascia iliaca block; bupivacaine;
adrenaline
which covers it. This space is limited anteriorly byIntroduction
the fascia iliaca, posteriorly by the iliacus muscle,
The fascia iliaca compartment block has been medially by the vertebral column and upper sacrum
described as an alternative to femoral nerve block and laterally by the inner surface of the iliac crest.
and ‘three-in-one’ block for the provision of unilateral Distally the fascia iliaca blends with the fascia
analgesia in the lower limbs (1). The technique covering sartorius and is covered by fascia lata below
involves injection of local anaesthetic solution into the inguinal ligament and so the fascia iliaca
the fascia iliaca compartment which is a potential compartment extends to the lateral part of the upper
space between the iliacus muscle and the fascia iliaca thigh. The femoral, obturator and lateral cutaneous
nerves traverse the fascia iliaca compartment and
can be blocked by local anaesthetic solution deposited
Correspondence to: Dr E. Doyle, Department of Anaesthesia, Royal
in this compartment in the thigh if a sufficient volumeHospital for Sick Children, Sciennes Road, Edinburgh EH9 1LF,
Scotland, UK. is injected and upward migration is encouraged by
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the application distal pressure. The fascia iliaca
compartment block does not require the use of a
nerve stimulator or the production of parathesiae
and is performed away from blood vessels and nerves
so that the chances of inadvertent nerve injury or
intravascular injection of local anaesthetic are remote.
The technique has been shown to have a significantly
higher success rate (95%) than the ‘three-in-one’ block
in children (20%) (1).
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The technique requires a significant dose of local
Figure 1
anaesthetic solution near the maximum of 2.5 mg·kg−1 Plasma concentrations (median range) of bupivacaine in Groups
when bupivacaine is used and there are no data on the P and A. Ο Plain; Ε Adrenaline.
plasma levels reached when these doses are used for
available (Astra Pharmaceuticals) bupivacaine+the fascia iliaca compartment block. This study was
1/200 000 adrenaline (Group A).carried out to determine the plasma concentrations
Following injection, venous blood samples (1 ml)reached when the fascia iliaca compartment block is
were taken at 5, 10, 15, 20, 25, 30, 40, 50 and 60 min.performed in children with 2 mg·kg−1 of 0.25%
These were taken after removal of 5 ml of ‘dead space’bupivacaine with and without adrenaline.
blood and immediately placed in crushed ice. Samples
were centrifuged at 4°C for 15 min and the plasma
removed and stored at−20°C until analysis. PlasmaMethods
samples were made alkaline by the addition of 0.5 ml
of 1 M NaOH and extracted with 6 ml of diethyl ether.The study was approved by the hospital ethics
The ethereal layer was transferred to a tapered glasscommittee and written informed parental consent
tube containing 1 ml 1 M HCl. The samples andwas obtained for each child recruited in to the study.
standards were roller mixed for 20 min and the etherTwenty children aged from 1 to 14 years undergoing
layer removed and discarded. The remaining solutionunilateral removal of a femoral plate were recruited.
was make alkaline by the addition of 1 ml 4 M NaOHSubjects were premedicated with EMLA cream one
and finally extracted in 75 ll of chloroform. Aliquotshour preoperatively and anaesthesia was induced
of 1 ll were then injected directly onto the highwith propofol 3–4 mg·kg−1. A laryngeal mask airway
performance liquid chromatography column. Peakwas inserted and anaesthesia maintained with
height ratios for the drug and internal standard wereisoflurane 0.5–2% with 70% nitrous oxide in oxygen.
used to construct a standard graph of concentrationA second intravenous cannula was then sited for
versus peak height ratio. An external quality controlblood sampling.
was run in conjunction with each batch of analyses.A fascia iliaca compartment block was performed
When patients had recovered from anaesthesia theat a point 1–2 cm perpendicularly below the junction
presence of an adequate block was tested by skinof the lateral one third and medial two thirds of the
pinching in the appropriate areas. The duration ofinguinal ligament. A 22 G short bevelled regional
the block was taken as the time to administrationblock needle was connected to a syringe of local
of first postoperative analgesia as determined by aanaesthetic solution by a length of plastic tubing and
request for analgesia from parent or child.inserted perpendicular to the skin and advanced
Statistical analysis was performed with Student’sslowly until a distinct double pop was felt as it
t-test for parametric data (age and weight) and thepierced first the fascia lata and then the fascia iliaca.
Mann-Whitney U-test for bupivacaine concentrations.After a negative aspiration test the local anaesthetic
solution was injected while firm pressure was exerted
distal to the injection site. The dose used was Results
2 mg·kg−1 (0.8 ml·kg−1) of 0.25% bupivacaine.
Patients were randomly allocated to receive either The samples from one patient were lost and this
subject was excluded from the results of the study.plain bupivacaine (Group P) or commercially
 1997 Blackwell Science Ltd, Paediatric Anaesthesia, 7, 121–124
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Table 1 bupivacaine. The median times taken to reach these
Demographic and operative data on patients in Groups P and levels are similar to those seen in studies of caudalA
epidural analgesia in children where the times taken
Group P Group A range from 15 to 45 min (4,5,7–9) compared with less
than 10 min after intercostal injection of bupivacaine
Age/yrs Mean (SD) 7.7 (4.2) 7.6 (4.1)
in infants (9,10). These figures suggest that the fasciaWeight/kg Mean (SD) 26.8 (10.2) 30 (14.8)
M:F 4:5 4:6 iliaca compartment is a relatively avascular space
L:R 5:4 4:6 compared with the intercostal space and that the
absorption of local anaesthetics from it is relatively
slow and may be further reduced by the use of
adrenaline containing solutions.
The two groups were comparable in terms of No attempt was made to follow the elimination
demographic characteristics and operative curve of bupivacaine in this study because the
procedures (Table 1). elimination characteristics of bupivacaine in healthy
All subjects in both groups were pain free on children are well described (9,11).
recovery from anaesthesia and were demonstrated The addition of adrenaline to bupivacaine did not
to have an appropriate area of sensory blockade at appear to prolong the duration of the fascia iliaca
this time. compartment blocks in this study.
Plasma concentrations of bupivacaine were In summary, this study has confirmed the efficacy
compared and are illustrated in Figure 1. of the fascia iliaca compartment block in children
Plasma concentrations of bupivacaine in Group P and shown that when performed with 2 mg·kg−1 of
were significantly higher than those in Group A at bupivacaine is associated with plasma concentrations
all times (P<0.05). The median maximum plasma of bupivacaine well within acceptable limits. The
concentration (Cmax) was 1.1 lg·ml−1 (range addition of adrenaline 1/200 000 to the local
0.54–1.29 lg·ml−1) in Group P and 0.35 lg·ml−1 (range anaesthetic solution reduces the maximum plasma
0.17–0.96 lg·ml−1) in Group A. The median time taken concentration reached but does not appear to prolong
to attain (Cmax) (Tmax) was 20 min (range 10–25 min) the duration of the block.
in Group P and 45 min (range 5–50 min) in Group
A.
One subject in Group P did not ask for further Acknowledgement
analgesia. The median time to first analgesia in the
We are grateful to Iain McDonald and Mark Drottarremaining subjects was 9.75 h (range 3–15 h) in Group
of the Department of Anaesthesia, University ofP and 10.5 h (range 2.5–21 h) in Group A. It was
Glasgow for performing the bupivacaine assays infelt that the Groups were too small for statistical
this study.comparisons of the duration of analgesia to be useful.
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The minimum effective dose of lignocaine to prevent injection pain due to propofol in children 
E. Cameron,  MA, MRCP, FRCAnaes ,  Registrar, G. Johnston,  M B ,  ChB, FRCAnaes ,  Senior Registrar, 
S. Crofts, MB,  ChB,  FRCAnaes, Registrar, N.S. M o r t o n ,  MB, ChB,  FFARCS, Consul tant ,  Depar tment  of 
Anaesthesia, Royal Hospital for Sick Children, Glasgow G3 8SJ. 
Summary 
In a single-blind study of 100 children aged I to 10 years, the minimum eflective dose of lignocaine required to prevent injection 
pain due to propofol was 0.2 mg.kg-' when veins on the dorsum of the hand were used. This is more than twice the adult value. 
We concluded that injection pain should not limit the use of propofol in children if an adequate amount of lignocaine is mixed 
immediately prior to injection. 
Key words 
Anaesthetics, intravenous; propofol. 
Anaesthetics local; lignocaine. 
Complications; pain 
Injection pain is the commonest problem encountered 
when propofol is administered, occurring in up to 73% of 
adults [l], and 85% of children [2]. One successful strategy 
for pain prevention is the addition of lignocaine to 
propofol immediately before injection [3,4]. In a group of 
50 unpremedicated children, lignocaine (1 mg.kg- I) mixed 
with propofol (3 mg.kg-') resulted in abolition of injection 
pain [S]. However, this dose of lignocaine was chosen 
empirically and the aim of the present study was to deter- 
mine the minimum effective dose of lignocaine. 
Methods 
The study was approved by the hospital Ethics Committee 
and was carried out under the automatic exemption condi- 
tions of the Medicines Act 1965 (revised 1985) [6]. 
Informed consent was obtained from the parents of 100 
children, 50 aged 1 to < 5 years and 50 aged 5 to < 
10 years. Children with known sensitivity to  local anaes- 
thetics, egg protein, soya bean emulsion or a significant 
history of atopy were specifically not studied. No sedative 
or anticholinergic premedication was used but all children 
had EMLA cream applied to the dorsum of each hand at 
least 1 h before venous cannulation (22 gauge Venflon, 
Vygon UK). 
Propofol 3 mg.kg-' was drawn up into a syringe and 
lignocaine was mixed immediately before injection 
according to the following scheme: the first child in each 
age group received lignocaine 1 mg.kg-'. If no pain on 
injection was observed then the next child received a dose 
of lignocaine reduced by 0.1 mg.kg-'. This sequence was 
followed until pain was observed when the next patient 
received 0.1 mg.kg-' increased dose of lignocaine. 
Injection pain was assessed by an observer who was 
unaware of the lignocaine dose used. A four point beha- 
I 
~ e e e e e e e e  
I 
I 
e l  
I 
I 
I 
I 
I 
I 
I 
I 
I 
I 
0 0.2 0.4 0.6 0.8 I .o 
Lignocaine dose (mg kg-') 
Fig. 1. Percentage of children aged I to 10 years where no pain was 
observed at each lignocaine dose level. No child who received 
0.2mg.kg-l or more experienced pain. 22.5% of children who 
received 0.1 mg.kg-' experienced pain. 
vioural rating scale was used (no pain = 0; mild pain 
(grimace) = 1; moderate pain (grimace+cry) = 2; severe 
pain (cry+withdraw limb) = 3). 
Results 
One hundred children were studied. Their median age was 
5.5 years (range 1.08-9.83) and their median weight was 
22.7 kg (range 9.7-35.7). The proportion of children in 
whom no injection pain occurred is detailed for each dose 
level of lignocaine in Figure 1 .  No child was assessed as 
having injection pain who received 0.2 mg.kg-' or more of 
Correspondence should be addressed to Dr N. S .  Morton, please. 
Accepted 12 February 1992. 
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Fig. 2(a). Pain on injection scores for children aged I to < 5 years receiving 0.1 (H) and 0.2 (m) mg.kg-' lignocaine (0 = no pain; I = mild 
pain; 2 = moderate pain; 3 = severe pain). (b) Pain on injection scores for children aged 5 to 10 years receiving 0. I (H) and 0.2 (m) mg.kg-' 
lignocaine (0 = no pain; 1 = mild pain; 2 = moderate pain; 3 = severe pain). If pain on injection was experienced, i t  tended to be more severe 
in younger children, aged I to < 5 years. 
lignocaine. 22.5% of children who had received 
0.1 mg.kg-' lignocaine were assessed as having injection 
pain. Pain was assessed as being moderate or severe in five 
patients in the I to  < 5 year age group (Figs 2(a) and (b)). 
Discussion 
One method of preventing injection pain due to propofol in 
adults, is to use a large antecubital vein [4]. In children, this 
results in injection pain in 6.6% [i'] to 24% [8].  However, 
the antecubital fossa carries the risk of arterial or neural 
damage and in children the availability of EMLA cream 
has made painless cannulation of veins on the dorsum of 
the hand the preferred choice of most anaesthetists. 
This study confirmed the efficacy of added lignocaine in 
preventing injection pain due to propofol. However, an 
adequate dose must be used in children where 22.5% of 1 
to 10 year olds experienced pain despite the addition of 
0.1 mg.kg-' lignocaine to 3 mg.kg-' propofol. In younger 
children aged 1 to  5 years, injection pain tends to  be more 
severe. In adults, the minimum effective dose of lignocaine 
to prevent injection pain is 0.08 mg.kg-' (0.025%) (91, 
whereas our study indicates that for children aged 1 to 10 
years, 0.2 mg.kg-' is required. Thus, children's veins would 
appear to be twice as susceptible to this adverse effect of 
propofol. 
Previous studies in children have used an adaptation of 
the recommended adult regimen of 10mg lignocaine per 
200 mg propofol [lo, 1 I]. At an induction dose of 
3 mg.kg-' this produces a lignocaine dose of 0.15 mg.kg-'. 
However, these studies found an incidence of injection pain 
of 29% and 60% respectively. Efficacy of added lignocaine 
is known to decline after 30 min [ 121 and it is possible that 
mixing immediately before, administration in the present 
study was responsible for the efficacy of 0.2 mg.kg-'. Any 
delay between mixing lignocaine with propofol and 
administration may result in a critical reduction in the 
concentration of lignocaine in the nonlipid phase of the 
emulsion, i.e. in the amount available to block afferent 
nerve fibres in the vein wall [13]. 
We conclude that the minimum effective dose of ligno- 
caine required to prevent injection pain due to propofol 
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3 mg.kg-' in children is 0.2 mg.kg-l. Injection pain is not a 
problem in children who receive propofol if an adequate 
amount of lignocaine is mixed with the propofol immedi- 
ately before administration. 
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Analysis of unconjugated morphine, codeine, 
normorphine and morphine as glucuronides in small 
volumes of plasma from children 
D.G. WATSON,*t Q. SU,t J.M. MIDGLEY,+ E. DOYLE$ and N.S. MORTON$ 
+ Department of Pharmaceutical Sciences, University of" Strathclyde, Glasgow G1 1XW, UK 
$ Department of Anaesthesia, Royal Hospital for Sick Children, Yorkhill, Glasgow G3 8S J, UK 
Abstract: A sensitive method for the analysis of unconjugated morphine, codeine, normorphine and total morphine after 
hydrolysis of glucuronide conjugates i described. The method was applicable to 50-p,1 volumes of plasma. The analytes 
were converted to heptafluorobutyryl (HFB) derivatives before analysis by gas chromatography-negative ion chemical 
ionization mass spectrometry. Morphine and codeine were quantified against their [2H3]-isotopomers. Linearity, 
precision and accuracy were quite acceptable (in the 10-~°-10-~ g range), and the absolute limits of detection were 
< 1 pg. 
Keywords: GC-MS; morphine; morphine ghwuronides; codeine; normorphine. 
Introduction 
Post-operative relief of pain in children has 
been carried out using opioids in a continuous 
infusion for a number of years [1]. The 
subcutaneous route for delivery of the drug has 
been used for many years in the terminal care 
of adults is subcutaneous delivery [2] and this 
route is an attractive means of delivering the 
drug to children since it avoids intramuscular 
injections or the conventional continuous in- 
fusion, where access to, and the preservation 
of, small veins may be difficult [3]. Pharmaco- 
kinetic data for this means of delivering 
morphine has been obtained for adults [4] but 
not for children. In order to develop this type 
of protocol more fully, and assess the efficacy 
of the procedure it is necessary to obtain data 
on the concentrations of morphine and its 
metabolites in plasma following subcutaneous 
administration to children. The samples of 
blood that can be obtained from children 
during a pharmacokinetic study are necessarily 
small and limited by ethical constraints. Thus a 
sensitive and discriminating method was 
required in order to make multiple measure- 
ments of morphine and its metabolites in such 
small volumes of plasma. 
Morphine is converted in the liver to its 
glucuronide metabolites and most of the 
morphine present in plasma, particularly after 
oral dosing, is in the form of its 3-glucuronide 
(M3G). The 6-glucuronide of morphine (M6G) 
is a potent analgesic [5, 6] and may also be 
present in plasma; at ca  10% of the concen- 
tration of M3G [5]. The amount of M3G in 
plasma following oral dosing is 10-50 times the 
amount of morphine, and thus M6G [6, 7] may 
be present in plasma in greater amounts than 
morphine. 
A number of methods based on HPLC or 
GC-MS have been developed for the analysis 
of morphine [8-14]. Fewer methods have been 
developed for the analysis of the glucuronide 
metabolites of morphine, and the existing 
methods for the measurement of these com- 
pounds based on HPLC [7-11] are difficult to 
use and lack sensitivity; more sensitive 
methods have to be used for small volumes of 
samples. Recently, an elegant refinement of 
radioimmunoassay (RIA) technique has been 
described which was able to determine both 
morphine and M6G by using different antisera 
[15]. The method was validated using an 
established HPLC method. GC-MS methods 
cannot compete with RIA methods for speed 
but they are more specific than either HPLC or 
RIA methods. 
* Author to whom correspondence should be addressed. 
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In this paper we describe avery sensitive and 
specific GC-MS method for measuring uncon- 
jugated morphine, codeine, normorphine and 
morphine as glucuronide(s) in small volumes of 
plasma from children. 
Experimental 
Chemicals 
All solvents used were HPLC grade (Rath- 
burn Chemicals, Peebleshire, UK). Chemicals 
and standards were obtained from the follow- 
ing sources: morphine sulphate pentahydrate, 
codeine free base, [2H3] morphine, [2H3] 
codeine, normorphine hydrochloride di- 
hydrate, morphine 3-glucuronide, morphine 6- 
glucuronide dihydrate, glucuronidases from 
Escherichia coli, bovine liver, Helix pomatia, 
Patella vulgata and Chlamys opercularis (the 
Sigma Chemical Co., Dorset, UK); hepta- 
fluorobutyric anhydride (Aldrich Chemical 
Co., Dorset, UK). 
Plasma samples 
Morphine was infused subcutaneously at
rates between 5 and 25 iLg kg -1 h -1. Samples 
of blood (1 ml) were collected at 4-h intervals 
from children receiving subcutaneous 
morphine infusion up to a total of 10 ml. The 
samples (up to a total of 1 ml kg -t of body 
weight or 10 ml maximum regardless of body 
weight) were collected into a lithium heparin 
tube and then centrifuged, the plasma removed 
and the sample stored at -20°C until analysis. 
Treatment of samples 
The volume of plasma obtained from 1 ml of 
blood was ca 0.5 mi. An aliquot of sample 
(300 iLl) was withdrawn and to this were added 
15 ng of [2H3] morphine (15 iLl of a 1 ng ix1-1 
solution in water) and 15 ng of [2H3] codeine 
(15 iLl of a 1 ng iLl -I solution in water). 
(i) In order to determine unconjugated 
morphine in the spiked plasma sample two 
aliquots (each of 55 iLl) were withdrawn and 
phosphate buffer (55 iLl, 0.1 M, pH 6.8) was 
added to each, this was followed by addition of 
ammonia buffer (300 iLl, 1 M, pH 9.5) and 
extraction with ethyl acetate (2 × 1 ml). The 
ethyl acetate was then removed under a stream 
of nitrogen and heptafluorobutyric anhydride 
(50 iLl) was added to the residue. The solution 
was heated (15 min, 60°C), the reagent was 
then removed under a stream of nitrogen, the 
residue was dissolved in ethyl acetate (100 iLl) 
and 4 iLl were injected into the GC-MS. 
(ii) In order to determine 3MG and 6MG 
the remaining plasma (220 iLl) was mixed with 
phosphate buffer (220 iLl, 0.1 M, pH 6.8) 
containing E. coli glucuronidase (2 mg m1-1) 
and the mixture was then incubated at 42°C for 
18 h. Two aliquots of ll0-iLI were withdrawn 
and treated as described in (i) starting from 
" . . .  followed by addition of ammonia 
buf fe r . . . " .  
Calibration curve 
The following solutions of standards were 
prepared 
(a) [eH3] morphine, [2H3] codeine (each 
1 ng ILl-J). 
(b) Morphine, codeine and normorphine 
(0.05 ng ix1-1) + M3G and M6G (each 0.1 ng 
iLl-l). 
(C) Morphine, codeine and normorphine 
(each 0.2 ng iLl -I ) + M3G and M6G (each 
0.4 ng iLl-l). 
(d) Morphine, codeine and normorphine 
(each 0.8 ng iLl -1) + M3G and M6G (each 
1.6 ng iLl-l). 
(e) Morphine, codeine and normorphine 
(each 3.2 ng iLl-t). 
Samples of plasma (300 iLl) were spiked as 
follows; 
(i) 15 iLl of solution (a) + 15 iLl of water; 
(ii) 15 iLl of solution (a) + 15 iLl of solution 
(b); 
(iii) 15 iLl of solution (a) + 15 iLl of solution 
(c); 
(iv) 15 iLl of solution (a) + 15 iLl of solution 
(d); 
(v) 15 iLl of solution (a) + 15 iLl of solution 
(e). 
The spiked plasma samples (330 iLl) were 
then treated as described under Treatment of 
samples. 
Replicate precision 
The following solutions of standards were 
prepared; 
(a) [2H3] morphine and [2H3] codeine (each 
of 1 ng ILl-l); 
(b) Morphine, codeine and normorphine 
(each of 0.2 ng ILl -1) and M6G and M3G (each 
of 0.4 ng ILl-I). 
A sample of blank plasma (1 ml) was spiked 
with 50 ILl of solution (a) and 50 ILl of solution 
(b) and mixed thoroughly. 
(i) Five aliquots (each of 55 ILl) were with- 
drawn and processed according to Treatment of 
samples (i). 
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(ii) The remaining plasma (0.825 ml) was 
mixed with phosphate buffer (0.825 ml, 0.1 M, 
pH 6.8) containing 2 mg m1-1 glucuronidase 
and the mixture was incubated at 42°C for 
18 h. Five aliquots (each of 110 pA) were 
withdrawn and processed as previously ali- 
quots described under Treatment of samples. 
Instrumentation 
A Hewlett-Packard 5998A GC-MS system 
was used. Analysis was carried out in the 
negative ion chemical ionization (NICI) mode. 
Methane was introduced to give a source 
pressure of ca 1 Tort. The GC was fitted with a 
Hewlett-Packard HP-1 column (12 m × 
0.25 mm i.d. x 0.33 ~m film), helium was 
used as a carrier gas with a head pressure of 5 
p.s.i. The GC injector temperature was 250°C 
and the interface temperature was 280°C. The 
oven was programmed as follows: 100°C 
(1 min)/20°C min -1 to 250°C and then 2°C 
min ~ to 257°C. The mass spectrometer was 
tuned to the ions for the PFTBA calibrant at 
m/z 452,595 and 633. 
Results and Discussion 
Figure 1 shows the mass spectrum of 
morphine di HFB derivative obtained under 
NICI conditions. The principal ions are the 
molecular ion at m/z 657, an ion at m/z 637 
(resulting from loss of HF from the molecular 
ion), an ion at m/z 441 (due to a less straight- 
forward fragmentation, probably involving 
addition of hydrogen followed by loss of HF 
and HFB) and a reagent specific ion (at m/z 
197) which is the base peak. Selected ion 
monitoring was carried out for the ions at m/z 
657 and m/z 637 in the analysis of morphine 
[2H3] morphine di HFB gave corresponding 
ions with the addition 3 a.m.u. HFB deriv- 
atives of normorphine and codeine also gave 
simple mass spectra under NICI conditions. 
Table 1 summarises the mass spectral and 
retention index data obtained for morphine 
and related compounds. Figure 2 shows an 
SIM trace for the HFB derivatives of a mixture 
of morphine, codeine and normorphine spiked 
at 0.38, 0.5 and 0.42 ng per 50 ~1 of plasma 
(the concentrations are expressed in terms of 
the free bases), respectively. The trace rep- 
resents injection of ca 20 pg of each compound 
on column and these are compared with [2H3] 
morphine and [2H3] codeine spiked at 2.5 ng 
per 50 pA of plasma (ca 100 pg of each on 
column). The absolute limits of detection of 
the HFB derivatives of these compounds were 
below 1 pg. 
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Figure 1 
The mass spectrum of morphine diHFB derivative under NICI conditions. 
Table 1 
Mass spectral and chromatographic data 
Compound Base peak M Other major ions l value 
Morphine 197 657 (12.9) 637 (21.5), 441 (26.8) 2333 
[2H3] morphine 214 660 (14.1) 640 (22.3), 444 (34.6) 2332 
Codeine 475 475 (100) 213 (88.5) 2338 
[2Ha] codeine 478 478 (100) 213 (85.7) 2336 
Normorphine 623 839 (7.8) 603 (34.7), 213 (56.8) 2404 
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Figure 2 
SIM trace showing the HFB derivatives of morphine, 
codeine and normorphine (0.2 ng per sample) in com- 
parison with [2H3] morphine and codeine (2.5 ng per 
sample). 
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Release of morphine from M3G and M6G incubated with 
glucuronidase from E. coil  
Glucuronidases from H. pomatia, P. 
vulgata, C. opercularis, bovine liver and E. coli 
were tested for their ability to hydrolyse M3G 
and M6G and it was found that the E. coli 
glucuronidase was the most effective. The 
other enzymes gave <10% hydrolysis of the 
more readily hydrolysed M3G after 30 min. 
The H. pomatia enzyme has been used by a 
number of workers [16-18] and an early paper 
on its use [16] would seem to indicate that it 
only gives about 10% hydrolysis of M3G after 
1 h whereas in our case the E. coli enzyme 
gave >80%. Acid hydrolysis has been com- 
monly used to release morphine from its 
conjugates [14, 19], but here it was found that 
even mild acid hydrolysis led to extensive 
degradation. Typical curves for the hydrolysis 
of M3G and M6G by the E. coli glucuronidase 
are shown in Fig. 3. The hydrolysis of M3G 
was ca 70% complete in 30 min, whereas the 
hydrolysis of M6G was only ca 27% compete at 
this time. In principle, this provides a means of 
distinguishing between the two glucuronides 
but, in practice, the fact that M3G is 5-10 
times more abundant hat M6G in plasma [5] 
means that such a distinction is not possible 
within the limits of precision of the method. 
The estimates for morphine as glucuronide 
are thus based on the curve constructed using 
morphine sulphate as a standard rather than 
curves constructed for the glucuronides. The 
reason for this was that the commercial glucur- 
onides were not pure as judged from the peak 
area for the morphine released after 18 h of 
hydrolysis compared to a calibration curve 
based on morphine sulphate, and the purities 
of M3G and M6G can be estimated as being ca 
78 and 64%, respectively. It is not clear 
whether or not these standards have been fully 
authenticated and it is likely that they contain 
undefined amounts of absorbed water or exist 
in the form of more than one hydrate. 
Calibration curves were constructed for 
morphine, codeine and normorphine by 
monitoring the selected ions for the com- 
pounds and deuteriated internal standards 
given in Table 2. Normorphine was quantified 
against [2H3] morphine. The curves were con- 
structed with respect o the compounds as their 
free bases and were linear over the following 
ranges: morphine 0.095-6.08 ng per 50 ~1 of 
plasma; codeine 0.125-8.0 ng per 50 pJ of 
plasma; and normorphine 0.105-6.72 ng per 
50 p~l of plasma. 
The precision and accuracy for the analysis 
of five samples of morphine (0.38 ng per 50 I~1 
of plasma), codeine (0.5 ng per 50 p,l of 
plasma) and normorphine (0.42 ng per 50 I~1 of 
plasma) was determined, and is shown in Table 
3. The accuracy of the method was determined 
by comparing the amount of morphine, 
codeine or normorphine calculated from the 
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Table 2 
Calibration curve details for morphine, codeine and normorphine 
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Compound Ion ratio used to prepare curve 
Morphine m/z 637 + 657 
m/z 641) + 660 
Codeine rn/z 475 
m/z 478 
Normorphine mlz 839 + 623 
m/z 640 + 660 
Equation of line Corr. coeff. Range ng per 5() ill 
y = 1.2522x -- 0.0143 0.9998 ().()95-6.()8 
y = 0.7044x -- 0.0170 0.9914 (). 125-8.0 
y = 1.2536x -- 0.2360 0.9964 0. 105-6.72 
Table 3 
Precision and accuracy of morphine, codeine and nor- 
mofphine in subnanogram amounts 
Amt spiked per Accuracy Precision 
Compound 50 ixl plasma n = 5 n = 5 
Morphine 0.38 ng 97.1% _+10.6% 
M3G + M6G 0.8 ng each - -  _+14.6%* 
Codeine 0.5 ng 94.0% _+8.8% 
Normorphine 0.42 ng 111.9% _+ 11.8% 
*Determined after incubation for 18 h with glu- 
curonidase. 
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4~ -MIZ640.660 ~.~ . 
I 
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i I 
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M/Z 623.839 
0 .z ,~ ' - -~  
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Figure 4 
SIM trace showing morphine in a sample of plasma (50 ILl) 
from a child receiving morphine via subcutaneous infusion 
for 24 tl. Of [2H3] morphine and codeine, 2.5 ng were 
added as internal standards. 
analytical data using tile calibration curve in 
comparison with the known amount of these 
compounds spiked into the sample. The pre- 
cision of the analysis of M3G + M6G (0.8 ng 
per 50 txl of plasma) after incubation with 
glucuronidase for 18 h was determined, it was 
not possible to determine the accuracy in view 
of the doubts about the purity of the standards. 
The precision was quite good for deter- 
mination of compounds at this level, the main 
source of imprecision was the difficulty of 
getting exactly reproducible integration with 
respect o the chromatographic baseline. 
Figure 4 shows derivatized unconjugated 
morphine extracted from plasma (501xl) 
following subcutaneous infusion of morphine 
for 24 h into a child comparison with standard 
derivatized [2H3} morphine (2.5 ng per 50 txl). 
Figure 5 shows the same sample after treat- 
ment with glucuronidase for 18 h, indicating a
large increase in the peak for morphine. After 
hydrolysis of the plasma samples with glucur- 
onidase, it was possible to detect small 
amounts of normorphine. In some samples 
small amounts of codeine were detected at 
levels close to the limit of detection. Table 4 
shows some preliminary results obtained after 
the analysis of plasma following the continuous 
5t~1963"/*657 . /~RPH , 
D3-COD 
101 -M/Z478 ~ 
l 
M/_Z 475 
• M/~ 623 ~39 NMOI~H 
9.5 I0.0 MIN 10.5 
Figure 5 
SIM trace showing morphine and normorphine in a sample 
of plasma (50 ~1) from a child receiving morphine via 
subcutaneous infusion for 24 h. After hydrolysis with 
glucuronidase. Of [2H3] morphine and codeine, 2.5 ng 
were added as internal standards. 
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Table 4 
The variation of the concentration of unconjugated and total morphine and total normorphine with time of subcutaneous 
infusion of morphine into children* 
Patient 1 Patient 2¢ 
Time Unconj. morphine Total morphine Total normorph. Unconj. morphine Total morphine Total normorph. 
(h) (rig ml -I) (ng ml -t) (ng ml -t) (rig ml ') (ng ml -I) (rig ml -I) 
11 4.72 + I).50 12.97 + 11.47 ND:[: 6.53 17.48 ND 
4 4.48 + I).17 14.4 _+ 0.76 ND 6.35 18.33 ND 
8 - -  - -  - -  3.82 13.77 ND 
14 4.94 + 0.21 39.78 + 2.52 1.00 -+ 0.511 - -  - -  - -  
18 6.73 __+ 0.71 49.65 __+ 0.72 0.89 __+ 0.07 - -  - -  - -  
22 6.35 -+ O. lO 58.1 -+ 1.50 0.96-+ 0.12 5.74 41.18 1.37 
24 5.24 __+ 0.57 47.97 __+ 0.88 0.96 -+ 0.06 5.78 __+ 0.24 47.18 + 6.64 2.48 -+ 0.72 
26 5.44 __+ 0.47 44.79 __+ 2.89 0.88 __+ 0.65 6.64 54.72 2.82 
28 7.52 + 0.32 58.54 + 2.20 1.30 -- 0.23 5.62 __+ 0.3 49.32 +__ 6.48 2.67 -+0.85 
* Codeine was below the limit of detection (ca 0.25 ng ml-i) in the 50-~1 samples 
-t Some single measurements were made on samples from this patient. 
SNot detected. 
analysed. 
subcutaneous infusion of morphine (5-25 Ixg 
kg -1 h -1) into children. 
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Abstract
The use of blood spot collection cards is a simple way to obtain specimens for analysis of drugs with a narrow
therapeutic window. We describe the development and validation of a microanalytical technique for the determination
of paracetamol and its glucuronide and sulphate metabolites from blood spots. The method is based on reversed
phase high-performance liquid chromatography with ultraviolet detection. The limit of detection of the method is 600
pg on column for paracetamol. Intra- and inter-day precision of the determination of paracetamol was 7.1 and 3.2%
respectively. The small volume of blood required (20 l), combined with the simplicity of the analytical technique
makes this a useful procedure for monitoring paracetamol concentrations. The method was applied to the analysis of
blood spots taken from neonates being treated with paracetamol. © 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Paracetamol (4-acetamidophenol) is the most
used analgesic and antipyretic drug in children
and neonates [1]. Despite its common use, phar-
macokinetic data about paracetamol is scarce,
especially in young infants and neonates. Due to
differences in their metabolism, there is special
interest in the levels of paracetamol in neonates,
particularly after multiple dosing [2–4].
In neonates, the volume of blood taken is lim-
ited by ethical considerations and thus a method
requiring only small volumes of blood is desir-
able. The use of a collection card similar to the
Guthrie paper card used for the sampling of small
volumes of blood allows more frequent sampling
while still complying with ethical guidelines of a
maximum 1 ml/kg body weight for blood sam-
pling from neonates. This paper describes the
development and validation of a microanalytical
technique for the determination of paracetamol
and its glucuronide and sulphate conjugates in
blood spots. The technique is based on high-per-
formance liquid chromatography (HPLC) with
ultraviolet detection. Due to the general availabil-
ity of liquid chromatographs coupled with the
* Corresponding author. Tel.: +44-141-548-2651; fax: +
44-141-552-6443.
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simplicity of blood spot sampling the technique
is well suited for the routine determination of
blood levels of paracetamol and its main
metabolites.
2. Materials and methods
2.1. Chemicals and reagents
Isolute ENV+ solid phase extraction car-
tridges (3 ml, 500 mg) were purchased from IST
(Mid Glamorgan, UK). Paracetamol and Hyper-
solv acetonitrile were obtained from BDH-
Merck (Poole, Dorset, UK). Ammonium
formate, 2-acetamidophenol and paracetamol
glucuronide were purchased from Sigma-Aldrich
(Poole, Dorset), and chlorosulfonic acid was
purchased from Fluka (Poole, Dorset).
2.2. Paracetamol sulphate synthesis
Paracetamol sulphate was synthesised accord-
ing to a published method [5]. The sulphate was
purified by solid phase extraction using Isolute
ENV+ cartridges (3 m1, 500 mg). The cartridges
were conditioned with 4 ml of methanol and 3
ml of water before loading the sample, which
was dissolved in distilled water. The potassium
chloride which was present in the paracetamol
sulphate isolated from the reaction mixture was
washed off with 3 ml of water and then the
paracetamol sulphate was eluted with 6 m1 (2×
3 m1) of methanol. The procedure was repeated
twice for the effluent collected during sample
loading in order to recover any paracetamol sul-
phate which had not been retained during the
first loading steps. Purity and identity of the
paracetamol sulphate were confirmed by HPLC,
electrospray mass spectrometry and 1H and 13C
NMR data. NMR spectra were acquired on a
Bruker AMX 400 MHz spectrometer using
deuterated DMSO as the solvent and the posi-
tive ion electrospray mass spectrum on a
Thermo-Finnigan Automass multi LC-GC/MS.
High resolution fast atom bombardment mass
spectrometry (FAB-MS) was carried out using a
JEOL 505HX instrument using the glycerol ma-
trix as the calibrant.
1H NMR (400 MHz, DMSO-d6,  from
TMS): 1.99 (3H, s, COCH3), 7.05 (2H, d, J=
8.76 Hz, H-3, H-5), 7.41 (2H, d, J=8.84 Hz,
H-2, H-6), 9.96 (1H, s, NH). 13C NMR (100
MHz, DMSO-d6,  from TMS): 168.80
(COCH3), 149.05 (C-4), 135.16 (C-1), 121.31 (C-
2, C-6), 120.20 (C-3, C-5), 24.06 (COCH3). Elec-
trospray Mass Spectrometry: m/z=232
[M+H]+base peak, m/z 151 [M-S03H]+. FAB-
MS gave the elemental composition of [M+H]+
as: C8H9NO5S with an error of 2.4 ppm.
2.3. Sample collection preparation
Samples were taken from an indwelling arte-
rial cannula placed for continuous blood pres-
sure monitoring of neonates and infants in a
paediatric intensive care unit. Single drops of
blood were collected on Guthrie-type cards
(Whatman, UK). For the purposes of calibration
and development of the method drops of blood
were taken from volunteers by finger-prick with
a lancet. Paper discs (7 mm) were sampled from
the blood spots with a hole puncher. The
punched paper disks were transferred to 3.5 ml
aluminium lined screw-capped vials and 200 l
of 20 mM ammonium formate buffer pH 3.5
was added. The samples were vortexed until
blood was extracted from the paper (1–2 min).
The internal standard (200 ng of 2-acetami-
dophenol) was added, and the samples were then
mixed with 3 ml of acetonitrile. After brief vor-
texing to precipitate the proteins, samples were
centrifuged (3500×g for 5 min) and the super-
natant transferred to another 3.5 ml vial. The
solvent was evaporated to dryness under a
stream of nitrogen and the residue was redis-
solved in 200 l of 20 mM ammonium formate
buffer pH 3.5. The sample was transferred to an
autosampler vial fitted with a 200 l glass insert
and 20 l was injected into the HPLC.
The volume of blood contained in the
punched blood spot disks was determined by
pipetting known volumes of blood (from 1 to 50
l) onto the paper cards with an automatic
pipette. The diameter of the blood spots were
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then measured and a calibration curve constructed.
A power equation (see below) was fitted and the
equation used to determine the volume of blood
contained in the punched disks used for analysis,
which had a fixed diameter of 7 mm. This proce-
dure gave a figure of 15.84 l of blood
Diameter of spot=2.0624
×volume of blood0.4423
(R2=0.996).
The relationship between blood volume pipetted
onto the cards and the diameter of the blood spot
was linear from 10 to 50 l. When a linear regres-
sion line was fitted between these points and the
equation of the line used to calculate the volume
of blood contained in 7 mm disks, the figure was
16.33 l of blood. The volume of 16 l of blood
was thus used for calculating the paracetamol
concentration in all the samples analysed.
2.4. Calibration solutions
Blood spots were collected from volunteers that
were not receiving treatment with paracetamol.
Punched paper disks were transferred to 3.5 ml
aluminium lined screw-capped vials and solutions
of standards (all prepared in acetonitrile) were
spiked onto the paper discs. The solvent was
evaporated to dryness under a stream of nitrogen
and 200 l of 20 mM ammonium formate buffer
pH 3.5 was added. The samples were then ex-
tracted as described above for sample preparation.
2.5. HPLC analysis
HPLC was carried out using a Thermosepara-
tions Spectra Series P4000 gradient pump coupled
with a Spectra System UV 6000 LP photodiode
array detector and a Thermoseparations AS1000
autosampler. The detector was set to scan from 200
to 500 nm and had a discrete channel set at 254 nm,
which was the wavelength used for quantification.
Separation was achieved using a Hypersil C18
column (75×4.6 mm, 3 m). The mobile phase
consisted of 20 mM ammonium formate buffer pH
3.5 (A) and methanol (B). The conditions of the
gradient are specified in Table 1.
Precision of the method was estimated by
analysing samples prepared by spiking blank blood
spots with each analyte. The blood spots were
extracted as described above for ‘sample collection
and preparation’. Intra-day precision was evalu-
ated by analysing a series of samples prepared and
analysed on the same day, while inter-day precision
analyses were done with samples prepared and
analysed on separate days (over a total period of
2 weeks). RSDs of less than 15% were considered
satisfactory.
The limit of detection was based a peak height
3X the largest baseline fluctuation in mAu in a 1
min window around the elution time of the analyte
in an analytical blank.
Recovery was calculated by comparing peak
areas obtained for each analyte in samples pre-
pared by spiking blank blood spots with peak areas
obtained for samples of buffer spiked with
Table 1
Gradient conditions for HPLC analysis
Flow (ml/min)20 mM ammonium formate pH 3.5 (%, v/v)Time (min) Methanol (%, v/v)
96.0 4.0 0.80.0
0.84.096.05.0
0.846.015.0 54.0
10.016.0 90.0 1.0
10.0 1.018.0 90.0
0.84.019.0 96.0
96.024.0 4.0 0.8
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Fig. 1. HPLC chromatograms showing separation of the analytes. (A) Sample prepared from a blank bloodspot. (B) A calibration
sample containing 600 ng/ml of paracetamol glucuronide (peak labelled 1), 600 ng/ml of paracetamol sulphate (peak labelled 2), and
300 ng/ml of paracetamol (peak labelled 3) extracted from a spiked blood spot. (C) A patient sample. The internal standard
(2-acetamidophenol) is labelled as 4 in the chromatograms. Detection by UV at 254 nm. For HPLC gradient conditions see Table
1.
the same amount of the analytes. Paracetamol
glucuronide and paracetamol sulphate were
spiked at a concentration of 200 ng/ml, paraceta-
mol was spiked at a concentration of 80 ng/ml,
and 2-acetamidophenol at a concentration of 1
g/ml. Recoveries above 80% were considered
satisfactory.
3. Results
Fig. 1 shows chromatograms of a blank sample
prepared from a blood spot (Fig. 1A), a calibra-
tion sample (Fig. 1B) prepared from a spiked
blood spot and a sample from a patient (Fig. 1C).
The chromatograms show that the analytes were
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well resolved from other endogenous components
of plasma. The retention times were 3.880.08
min for paracetamol glucuronide, 7.140.18
min for paracetamol sulphate, 9.560.05 min
for paracetamol and 11.640.05 min (mean
S.D., n=5) for 2-acetamidophenol (internal
standard).
The response of the detector was linear for all
the analytes (Table 2) over the concentration
range used during analysis of samples. Since the
detector response was lower for the metabolites
of paracetamol compared to paracetamol itself,
the limit of detection for paracetamol sulphate
and paracetamol glucuronide (2 ng on column)
was higher than that of paracetamol (600 pg on
column).
The recovery of the analytes by the extraction
procedure was estimated by comparing the peak
area obtained for the analytes spiked in blank
blood spot samples with the area of the analytes
spiked in buffer (Table 3). The recovery was
good and reproducible for paracetamol and the
internal standard (2-acetamidophenol). The more
variable recoveries obtained for the metabolites
are possibly a consequence of their polar nature
with correspondingly lower solubility in the ex-
traction solvent. The recovery of paracetamol
glucuronide was the most variable of all, which
is a reflection of both its high polarity and its
short retention time, which makes it more sus-
ceptible to interference from early eluting peaks.
The precision of the method (Table 4) was
evaluated by analysing samples spiked with stan-
dards in concentrations close to the limit of de-
tection. The samples were prepared and analysed
on the same day (Intra-day precision), or pre-
pared and analysed in different days (over a pe-
riod of 2 weeks) for estimating inter-day
precision. The precision was reasonable for a mi-
croanalytical method, and can possibly be im-
Table 2
Calibration curve parameters for paracetamol, paracetamol sulphate and paracetamol glucuronide
ParacetamolParacetamol glucuronide Paracetamol sulphate
(mean, RSD, n=3) (mean, RSD, n=3)(mean, RSD, n=3)
Slope 0.0005166, 10.7% 0.0007606, 3.1% 0.0028357, 7.3%
0.9978, 0.1% 0.9949, 0.6%r2 0.9973, 0.2%
160–4000 160–4000Range (ng) 40–2000
Table 3
Recovery of the analytes by the extraction procedure
Paracetamol glucuronide Paracetamol sulphate Paracetamol (%) 2-acetamidophenol (internal standard) (%)
(%)(%)
90.294.491.1Replicate 1 105.6
Replicate 2 76.090.9 93.9 86.9
Replicate 3 90.392.875.386.5
96.588.4 90.6106.4Replicate 4
Replicate 5 96.08 100.3 92.6 99.2
66.13 73.6Replicate 6 93.1 91.3
84.1Average 91.593.991.9
RSD% 12.816.2 1.5 4.5
Values are percentage of recovery when compared with the average peak area of the analytes spiked in buffer. Paracetamol
glucuronide and paracetamol sulphate were spiked at a concentration of 200 ng/ml, paracetamol was spiked at a concentration of
80 ng/ml, and 2-acetamidophenol at a concentration of 1 g/ml.
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Table 4
Intra- and inter-day precision of the method
Paracetamol sulphate (ng/ml) Paracetamol (ng/ml)Paracetamol glucuronide (ng/ml)
Intra-day precision
Replicate 1 145.3 160.5 39.9
134.8Replicate 2 46.4151.2
142.1150.7 41.6Replicate 3
165.0Replicate 4 139.8 46.8
190.1 42.2Replicate 5 155.2
153.5Average 43.4153.5
4.8RSD% 14.8 7.1
Inter-day precision
126.4162.9 42.1Replicate 1
182.9Replicate 2 139.8 43.6
132.2 41.2Replicate 3 209.9
169.2 40.4174.1Replicate 4
Average 182.4 141.9 41.8
13.4 3.2RSD% 11.0
The samples were spiked with a nominal concentration of 160 ng/ml for paracetamol glucuronide, 160 ng/ml of paracetamol
sulphate, and 40 ng/ml of paracetamol.
Fig. 2. Time profile of paracetamol concentration in blood spots taken from a neonate after a rectal dose of 20 mg/kg.
proved if a larger volume of sample were injected
or if the sample was prepared in more concen-
trated form (for example by diluting it to a final
volume of 100 l, instead of 200 l).
An example of the application of this method
to the determination of paracetamol concentra-
tions in blood spots from neonates is shown in
Fig. 2.
4. Discussion
Although widely used as an analgesic and an-
tipyretic, the pharmacokinetics of paracetamol in
young infants and neonates is not fully under-
stood. There are reports that paracetamol admin-
istered rectally in neonates at a dose of 20 mg/kg
body weight results in subtherapeutic concentra-
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tions [2,3]. Neonates are known to have a differ-
ent metabolic profile, and in the case of paraceta-
mol, sulphation is known to be the major route
for metabolism [4]. A better understanding of the
pharmacokinetics of paracetamol in neonates is
necessary to ensure that paracetamol plasma con-
centrations do not reach toxic or fall to subthera-
peutic levels, especially when multiple dosing is
being used. The development of sensitive and
selective methods for measuring paracetamol con-
centrations in biological fluids is an important
prerequisite of this endeavour.
Most methods for determining paracetamol in
biological samples use HPLC [6–8] or gas-chro-
matography [9–11]. Other methods include enzy-
matic and colorimetric techniques. Methods that
use a small volume of blood are desirable in
situations where the collection of larger volumes
are not feasible, such as in the case of neonates,
for which the volume of blood sampled is limited
by ethical guidelines. Also, other features which
are desirable are simplicity of sample preparation
and general availability of the analytical instru-
ment required for analysis. A recent method [12]
makes use of only 10 l of blood or plasma and
relies on HPLC with electrochemical detection for
quantification of paracetamol. The method de-
scribed here makes use of HPLC with ultraviolet
detection, which is widely available in biochemical
laboratories. It has the advantage of requiring
only a small sample volume (20 l) combined with
simple sample preparation and analysis. The ana-
lytes are well resolved from endogenous compo-
nents from the blood (Fig. 1) and the method can
be applied to detection of paracetamol and its
metabolites. The short retention time of paraceta-
mol glucuronide means that it is the analyte most
prone to suffer interference from polar compo-
nents eluting early in the run. However, in most
cases resolution from interfering peaks was
achieved. The use of new reversed phase columns
that can run 100% aqueous mobile phases
(through the use of stationary phases with polar
end-capping functionalities) might improve reten-
tion of the glucuronide and improve precision of
the method for this analyte.
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The use of blood spot collection cards is a simple way to obtain specimens for analysis of drugs with a narrow
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of paracetamol and its glucuronide and sulphate metabolites from blood spots. The method is based on reversed
phase high-performance liquid chromatography with ultraviolet detection. The limit of detection of the method is 600
pg on column for paracetamol. Intra- and inter-day precision of the determination of paracetamol was 7.1 and 3.2%
respectively. The small volume of blood required (20 l), combined with the simplicity of the analytical technique
makes this a useful procedure for monitoring paracetamol concentrations. The method was applied to the analysis of
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1. Introduction
Paracetamol (4-acetamidophenol) is the most
used analgesic and antipyretic drug in children
and neonates [1]. Despite its common use, phar-
macokinetic data about paracetamol is scarce,
especially in young infants and neonates. Due to
differences in their metabolism, there is special
interest in the levels of paracetamol in neonates,
particularly after multiple dosing [2–4].
In neonates, the volume of blood taken is lim-
ited by ethical considerations and thus a method
requiring only small volumes of blood is desir-
able. The use of a collection card similar to the
Guthrie paper card used for the sampling of small
volumes of blood allows more frequent sampling
while still complying with ethical guidelines of a
maximum 1 ml/kg body weight for blood sam-
pling from neonates. This paper describes the
development and validation of a microanalytical
technique for the determination of paracetamol
and its glucuronide and sulphate conjugates in
blood spots. The technique is based on high-per-
formance liquid chromatography (HPLC) with
ultraviolet detection. Due to the general availabil-
ity of liquid chromatographs coupled with the
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simplicity of blood spot sampling the technique
is well suited for the routine determination of
blood levels of paracetamol and its main
metabolites.
2. Materials and methods
2.1. Chemicals and reagents
Isolute ENV+ solid phase extraction car-
tridges (3 ml, 500 mg) were purchased from IST
(Mid Glamorgan, UK). Paracetamol and Hyper-
solv acetonitrile were obtained from BDH-
Merck (Poole, Dorset, UK). Ammonium
formate, 2-acetamidophenol and paracetamol
glucuronide were purchased from Sigma-Aldrich
(Poole, Dorset), and chlorosulfonic acid was
purchased from Fluka (Poole, Dorset).
2.2. Paracetamol sulphate synthesis
Paracetamol sulphate was synthesised accord-
ing to a published method [5]. The sulphate was
purified by solid phase extraction using Isolute
ENV+ cartridges (3 m1, 500 mg). The cartridges
were conditioned with 4 ml of methanol and 3
ml of water before loading the sample, which
was dissolved in distilled water. The potassium
chloride which was present in the paracetamol
sulphate isolated from the reaction mixture was
washed off with 3 ml of water and then the
paracetamol sulphate was eluted with 6 m1 (2×
3 m1) of methanol. The procedure was repeated
twice for the effluent collected during sample
loading in order to recover any paracetamol sul-
phate which had not been retained during the
first loading steps. Purity and identity of the
paracetamol sulphate were confirmed by HPLC,
electrospray mass spectrometry and 1H and 13C
NMR data. NMR spectra were acquired on a
Bruker AMX 400 MHz spectrometer using
deuterated DMSO as the solvent and the posi-
tive ion electrospray mass spectrum on a
Thermo-Finnigan Automass multi LC-GC/MS.
High resolution fast atom bombardment mass
spectrometry (FAB-MS) was carried out using a
JEOL 505HX instrument using the glycerol ma-
trix as the calibrant.
1H NMR (400 MHz, DMSO-d6,  from
TMS): 1.99 (3H, s, COCH3), 7.05 (2H, d, J=
8.76 Hz, H-3, H-5), 7.41 (2H, d, J=8.84 Hz,
H-2, H-6), 9.96 (1H, s, NH). 13C NMR (100
MHz, DMSO-d6,  from TMS): 168.80
(COCH3), 149.05 (C-4), 135.16 (C-1), 121.31 (C-
2, C-6), 120.20 (C-3, C-5), 24.06 (COCH3). Elec-
trospray Mass Spectrometry: m/z=232
[M+H]+base peak, m/z 151 [M-S03H]+. FAB-
MS gave the elemental composition of [M+H]+
as: C8H9NO5S with an error of 2.4 ppm.
2.3. Sample collection preparation
Samples were taken from an indwelling arte-
rial cannula placed for continuous blood pres-
sure monitoring of neonates and infants in a
paediatric intensive care unit. Single drops of
blood were collected on Guthrie-type cards
(Whatman, UK). For the purposes of calibration
and development of the method drops of blood
were taken from volunteers by finger-prick with
a lancet. Paper discs (7 mm) were sampled from
the blood spots with a hole puncher. The
punched paper disks were transferred to 3.5 ml
aluminium lined screw-capped vials and 200 l
of 20 mM ammonium formate buffer pH 3.5
was added. The samples were vortexed until
blood was extracted from the paper (1–2 min).
The internal standard (200 ng of 2-acetami-
dophenol) was added, and the samples were then
mixed with 3 ml of acetonitrile. After brief vor-
texing to precipitate the proteins, samples were
centrifuged (3500×g for 5 min) and the super-
natant transferred to another 3.5 ml vial. The
solvent was evaporated to dryness under a
stream of nitrogen and the residue was redis-
solved in 200 l of 20 mM ammonium formate
buffer pH 3.5. The sample was transferred to an
autosampler vial fitted with a 200 l glass insert
and 20 l was injected into the HPLC.
The volume of blood contained in the
punched blood spot disks was determined by
pipetting known volumes of blood (from 1 to 50
l) onto the paper cards with an automatic
pipette. The diameter of the blood spots were
E.J. Olieira et al. / J. Pharm. Biomed. Anal. 29 (2002) 803–809 805
then measured and a calibration curve constructed.
A power equation (see below) was fitted and the
equation used to determine the volume of blood
contained in the punched disks used for analysis,
which had a fixed diameter of 7 mm. This proce-
dure gave a figure of 15.84 l of blood
Diameter of spot=2.0624
×volume of blood0.4423
(R2=0.996).
The relationship between blood volume pipetted
onto the cards and the diameter of the blood spot
was linear from 10 to 50 l. When a linear regres-
sion line was fitted between these points and the
equation of the line used to calculate the volume
of blood contained in 7 mm disks, the figure was
16.33 l of blood. The volume of 16 l of blood
was thus used for calculating the paracetamol
concentration in all the samples analysed.
2.4. Calibration solutions
Blood spots were collected from volunteers that
were not receiving treatment with paracetamol.
Punched paper disks were transferred to 3.5 ml
aluminium lined screw-capped vials and solutions
of standards (all prepared in acetonitrile) were
spiked onto the paper discs. The solvent was
evaporated to dryness under a stream of nitrogen
and 200 l of 20 mM ammonium formate buffer
pH 3.5 was added. The samples were then ex-
tracted as described above for sample preparation.
2.5. HPLC analysis
HPLC was carried out using a Thermosepara-
tions Spectra Series P4000 gradient pump coupled
with a Spectra System UV 6000 LP photodiode
array detector and a Thermoseparations AS1000
autosampler. The detector was set to scan from 200
to 500 nm and had a discrete channel set at 254 nm,
which was the wavelength used for quantification.
Separation was achieved using a Hypersil C18
column (75×4.6 mm, 3 m). The mobile phase
consisted of 20 mM ammonium formate buffer pH
3.5 (A) and methanol (B). The conditions of the
gradient are specified in Table 1.
Precision of the method was estimated by
analysing samples prepared by spiking blank blood
spots with each analyte. The blood spots were
extracted as described above for ‘sample collection
and preparation’. Intra-day precision was evalu-
ated by analysing a series of samples prepared and
analysed on the same day, while inter-day precision
analyses were done with samples prepared and
analysed on separate days (over a total period of
2 weeks). RSDs of less than 15% were considered
satisfactory.
The limit of detection was based a peak height
3X the largest baseline fluctuation in mAu in a 1
min window around the elution time of the analyte
in an analytical blank.
Recovery was calculated by comparing peak
areas obtained for each analyte in samples pre-
pared by spiking blank blood spots with peak areas
obtained for samples of buffer spiked with
Table 1
Gradient conditions for HPLC analysis
Flow (ml/min)20 mM ammonium formate pH 3.5 (%, v/v)Time (min) Methanol (%, v/v)
96.0 4.0 0.80.0
0.84.096.05.0
0.846.015.0 54.0
10.016.0 90.0 1.0
10.0 1.018.0 90.0
0.84.019.0 96.0
96.024.0 4.0 0.8
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Fig. 1. HPLC chromatograms showing separation of the analytes. (A) Sample prepared from a blank bloodspot. (B) A calibration
sample containing 600 ng/ml of paracetamol glucuronide (peak labelled 1), 600 ng/ml of paracetamol sulphate (peak labelled 2), and
300 ng/ml of paracetamol (peak labelled 3) extracted from a spiked blood spot. (C) A patient sample. The internal standard
(2-acetamidophenol) is labelled as 4 in the chromatograms. Detection by UV at 254 nm. For HPLC gradient conditions see Table
1.
the same amount of the analytes. Paracetamol
glucuronide and paracetamol sulphate were
spiked at a concentration of 200 ng/ml, paraceta-
mol was spiked at a concentration of 80 ng/ml,
and 2-acetamidophenol at a concentration of 1
g/ml. Recoveries above 80% were considered
satisfactory.
3. Results
Fig. 1 shows chromatograms of a blank sample
prepared from a blood spot (Fig. 1A), a calibra-
tion sample (Fig. 1B) prepared from a spiked
blood spot and a sample from a patient (Fig. 1C).
The chromatograms show that the analytes were
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well resolved from other endogenous components
of plasma. The retention times were 3.880.08
min for paracetamol glucuronide, 7.140.18
min for paracetamol sulphate, 9.560.05 min
for paracetamol and 11.640.05 min (mean
S.D., n=5) for 2-acetamidophenol (internal
standard).
The response of the detector was linear for all
the analytes (Table 2) over the concentration
range used during analysis of samples. Since the
detector response was lower for the metabolites
of paracetamol compared to paracetamol itself,
the limit of detection for paracetamol sulphate
and paracetamol glucuronide (2 ng on column)
was higher than that of paracetamol (600 pg on
column).
The recovery of the analytes by the extraction
procedure was estimated by comparing the peak
area obtained for the analytes spiked in blank
blood spot samples with the area of the analytes
spiked in buffer (Table 3). The recovery was
good and reproducible for paracetamol and the
internal standard (2-acetamidophenol). The more
variable recoveries obtained for the metabolites
are possibly a consequence of their polar nature
with correspondingly lower solubility in the ex-
traction solvent. The recovery of paracetamol
glucuronide was the most variable of all, which
is a reflection of both its high polarity and its
short retention time, which makes it more sus-
ceptible to interference from early eluting peaks.
The precision of the method (Table 4) was
evaluated by analysing samples spiked with stan-
dards in concentrations close to the limit of de-
tection. The samples were prepared and analysed
on the same day (Intra-day precision), or pre-
pared and analysed in different days (over a pe-
riod of 2 weeks) for estimating inter-day
precision. The precision was reasonable for a mi-
croanalytical method, and can possibly be im-
Table 2
Calibration curve parameters for paracetamol, paracetamol sulphate and paracetamol glucuronide
ParacetamolParacetamol glucuronide Paracetamol sulphate
(mean, RSD, n=3) (mean, RSD, n=3)(mean, RSD, n=3)
Slope 0.0005166, 10.7% 0.0007606, 3.1% 0.0028357, 7.3%
0.9978, 0.1% 0.9949, 0.6%r2 0.9973, 0.2%
160–4000 160–4000Range (ng) 40–2000
Table 3
Recovery of the analytes by the extraction procedure
Paracetamol glucuronide Paracetamol sulphate Paracetamol (%) 2-acetamidophenol (internal standard) (%)
(%)(%)
90.294.491.1Replicate 1 105.6
Replicate 2 76.090.9 93.9 86.9
Replicate 3 90.392.875.386.5
96.588.4 90.6106.4Replicate 4
Replicate 5 96.08 100.3 92.6 99.2
66.13 73.6Replicate 6 93.1 91.3
84.1Average 91.593.991.9
RSD% 12.816.2 1.5 4.5
Values are percentage of recovery when compared with the average peak area of the analytes spiked in buffer. Paracetamol
glucuronide and paracetamol sulphate were spiked at a concentration of 200 ng/ml, paracetamol was spiked at a concentration of
80 ng/ml, and 2-acetamidophenol at a concentration of 1 g/ml.
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Table 4
Intra- and inter-day precision of the method
Paracetamol sulphate (ng/ml) Paracetamol (ng/ml)Paracetamol glucuronide (ng/ml)
Intra-day precision
Replicate 1 145.3 160.5 39.9
134.8Replicate 2 46.4151.2
142.1150.7 41.6Replicate 3
165.0Replicate 4 139.8 46.8
190.1 42.2Replicate 5 155.2
153.5Average 43.4153.5
4.8RSD% 14.8 7.1
Inter-day precision
126.4162.9 42.1Replicate 1
182.9Replicate 2 139.8 43.6
132.2 41.2Replicate 3 209.9
169.2 40.4174.1Replicate 4
Average 182.4 141.9 41.8
13.4 3.2RSD% 11.0
The samples were spiked with a nominal concentration of 160 ng/ml for paracetamol glucuronide, 160 ng/ml of paracetamol
sulphate, and 40 ng/ml of paracetamol.
Fig. 2. Time profile of paracetamol concentration in blood spots taken from a neonate after a rectal dose of 20 mg/kg.
proved if a larger volume of sample were injected
or if the sample was prepared in more concen-
trated form (for example by diluting it to a final
volume of 100 l, instead of 200 l).
An example of the application of this method
to the determination of paracetamol concentra-
tions in blood spots from neonates is shown in
Fig. 2.
4. Discussion
Although widely used as an analgesic and an-
tipyretic, the pharmacokinetics of paracetamol in
young infants and neonates is not fully under-
stood. There are reports that paracetamol admin-
istered rectally in neonates at a dose of 20 mg/kg
body weight results in subtherapeutic concentra-
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tions [2,3]. Neonates are known to have a differ-
ent metabolic profile, and in the case of paraceta-
mol, sulphation is known to be the major route
for metabolism [4]. A better understanding of the
pharmacokinetics of paracetamol in neonates is
necessary to ensure that paracetamol plasma con-
centrations do not reach toxic or fall to subthera-
peutic levels, especially when multiple dosing is
being used. The development of sensitive and
selective methods for measuring paracetamol con-
centrations in biological fluids is an important
prerequisite of this endeavour.
Most methods for determining paracetamol in
biological samples use HPLC [6–8] or gas-chro-
matography [9–11]. Other methods include enzy-
matic and colorimetric techniques. Methods that
use a small volume of blood are desirable in
situations where the collection of larger volumes
are not feasible, such as in the case of neonates,
for which the volume of blood sampled is limited
by ethical guidelines. Also, other features which
are desirable are simplicity of sample preparation
and general availability of the analytical instru-
ment required for analysis. A recent method [12]
makes use of only 10 l of blood or plasma and
relies on HPLC with electrochemical detection for
quantification of paracetamol. The method de-
scribed here makes use of HPLC with ultraviolet
detection, which is widely available in biochemical
laboratories. It has the advantage of requiring
only a small sample volume (20 l) combined with
simple sample preparation and analysis. The ana-
lytes are well resolved from endogenous compo-
nents from the blood (Fig. 1) and the method can
be applied to detection of paracetamol and its
metabolites. The short retention time of paraceta-
mol glucuronide means that it is the analyte most
prone to suffer interference from polar compo-
nents eluting early in the run. However, in most
cases resolution from interfering peaks was
achieved. The use of new reversed phase columns
that can run 100% aqueous mobile phases
(through the use of stationary phases with polar
end-capping functionalities) might improve reten-
tion of the glucuronide and improve precision of
the method for this analyte.
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Full Text
Plasma concentrations and pharmacokinetics of bupivacaine with and 
without adrenaline following caudal anaesthesia in infants
Abstract
Background: The aim of this study was to determine whether the use of adrenaline 1/400 000 added to 
0.25% bupivacaine significantly delays the systemic absorption of the drug from the caudal epidural space in 
young infants.
Methods: Fifteen infants less than 5 months of age undergoing minor lower abdominal procedures under a 
standardised general anaesthetic were randomised to receive a caudal block with either 0.25% plain bupivacaine 
2.5 mg/kg (n=7) or bupivacaine 0.25% with 1/400 000 adrenaline (n=8). Blood samples were drawn at 30, 60, 90, 
180, 240 and 360 min according to the infant's weight and analysed for total and free bupivacaine 
concentrations using a gas chromatography-mass spectrometry (GC-MS) technique.
Results: The total CMAX and TMAX were comparable in both groups. The total bupivacaine concentration at 
t=360 min was significantly higher in the "adrenaline" group compared to the "plain" group, i.e. a median (range) 
742 ng/ml (372-1423 ng/ml) vs. 400.5 ng/ml (114-446 ng/ml), P=0.0080. The median "apparent" terminal 
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half-life (t1/2) was significantly longer in the "adrenaline" group (363 min; range 238-537 min) compared to the 
"plain" group (n=6) (165 min; range 104-264 min), P=0.0087. The free bupivacaine concentrations (n=3 in both 
groups) ranged between 13 ng/ml and 52 ng/ml, corresponding to a percentage of free bupivacaine between 
1.3% and 6.7%.
Conclusion: The addition of 1/400.000 adrenaline prolongs the systemic absorption of caudally administered 
bupivacaine in infants less than 5 months of age.
Caudal epidural block with bupivacaine is by far the commonest regional anaesthetic technique used in 
small children (1-3). It combines the advantages of a fairly simple technique with a high success rate. The 
pharmacokinetics of caudally administered bupivacaine in young children, however, is still relatively little 
known (4-8).
The plasma protein binding capacity in infants is decreased (5, 9). This is an important issue when using 
highly plasma protein bound drugs such as bupivacaine. This reduction in binding capacity for bupivacaine will 
increase the free unbound fraction in infants, and thus increase the possibilities of toxic effects.
The "toxic" free plasma bupivacaine concentration following a single caudal bupivacaine dose is currently 
not known, but central nervous system toxicity in both adults and children has been described at total plasma 
bupivacaine concentrations in excess of 2 µg/ml (10).
By adding adrenaline to the bupivacaine solution it has been claimed that the systemic absorption of 
caudally (epidural) administered bupivacaine can be lowered considerably. Clinically, however, the addition of 
1/200 000 adrenaline to 0.25% bupivacaine has been found both to prolong the duration of the block (11) and to 
have no effects at all (12).
The aim of this study was to determine whether the use of adrenaline 1/400 000 added to 0.25% 
bupivacaine significantly delays the systemic absorption of the drug from the caudal epidural space in young 
infants.
Methods
Following ethical approval and written informed parental consent, 15 infants less than 5 months of age 
scheduled for minor lower abdominal surgery were enrolled in this study. Infants with any known renal or 
hepatic impairments were excluded as were infants suffering from contraindications to caudal anaesthesia. 
Preoperatively, the infants were randomised to receive a caudal block with either plain 0.25% bupivacaine (n=7) 
or 0.25% bupivacaine with adrenaline (1/400 000) (n=8). Sequential numbered opaque and sealed envelopes 
carried out randomisation. The total volume of 0.25% bupivacaine (with or without adrenaline) in each group 
was 1 ml/kg (=2.5 mg/kg).
Anaesthetic technique
Apart from the topical application of EMLA cream, no premedication was given. All infants received a 
standardised non-opioid-based general anaesthetic technique comprising induction with thiopenthone (3-5 
mg/kg) and atracurium (0.5 mg/kg). Following endotracheal intubation, the infants were ventilated to 
normocapnia with 40% O2 in N2O and desflurane (6-10%).
Subsequently, the infants were placed in the left lateral position and the caudal block performed using an 
aseptic technique and a 23 G needle. When negative aspiration of blood or cerebrospinal fluid had been 
confirmed, the calculated dose of bupivacaine (± adrenaline) was injected slowly and in increments into the
caudal space while watching vital signs and the electrocardiographic (ECG) monitor.
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After surgery, residual neuromuscular blockade was reversed with glycopyrrolate (10 µg/kg) and neostigmine
(50 µg/kg) and all children were extubated.
Blood sampling
Following the anaesthetic induction, a dedicated peripheral intravenous cannula (Venflon 22 G, Ohmeda, 
Sweden) was inserted in a saphenous vein for blood sampling. Patency of this cannula was maintained by an 
infusion of 5% glucose with 0.225% saline 3-5 ml/h.
Blood samples (0.7-1.0 ml/sample) were collected from the cannula at 30, 60, 90, 180, 240 and 360 min 
after the caudal block. After each blood sample the i.v. catheter was flushed with heparinised saline. The total 
number of blood samples from each individual was restricted by the Ethics Committee's limit of 1 ml/kg, but it 
was possible to sample from all but one infant at 30, 60 and 360 min. Older infants had additional samples 
drawn at intermediate time points according to weight.
The blood samples were then separated by centrifugation and plasma frozen at -20°C until assayed for total
bupivacaine. If possible (i.e. enough plasma), free bupivacaine concentrations were also measured.
Plasma bupivacaine (total and free) analysis
Total plasma bupivacaine concentrations were determined by addition of 100 ng of pentycaine to 200 µl of
plasma followed by addition of 200 µl of 0.5 M NaOH. The sample was extracted with ethyl acetate, the solvent
was removed and the residue was dissolved in 0.5 ml of 0.1 M phosphate buffer at pH 3.0. The sample was 
passed through a SCX (strong cation exchange) solid phase extraction cartridge (Isolute SCX, Crawford Scientific, 
Strathaven, Lanarkshire, UK) and was eluted with 1 M ammonia in methanol (1 ml). It was then blown to dryness 
and dissolved in ethyl acetate (0.1 ml) for analysis by gas chromatography-mass spectrometry (GC-MS). The GC-MS 
analysis was carried out using a Hewlett-Packard HP5988A GC-MS system in the electron impact (EI) mode; 
selected ion monitoring (SIM) was carried out for ions at m/z 140 for bupivacaine. The GC was fitted with a HP-1 
column, helium was used as a carrier gas at a pressure of 40 kPa and the GC oven was programmed as follows:
100°C for 1 min and 20°C/min increments to 320°C.
For analysis of the free plasma bupivacaine concentration an aliquot of plasma (200 µl) was diluted with 20
µl of 1 M phosphate buffer and was centrifuged (1000 g) in a Centrifree MPS ultrafiltration unit (Millipore,
Watford, UK). The ultrafiltrate was collected and 10 ng of pentycaine internal standard were added. The sample 
was then processed as described above (13, 14).
Pharmacokinetic analysis
For each infant, the maximal total plasma concentration (CMAX) and time to maximal plasma concentration 
(TMAX) were determined. The free plasma bupivacaine concentrations were measured in each individual sample 
over time in 3 infants from both groups. The free fraction (fµ) was calculated from the free concentration and the 
total concentration from measurements of 3-6 samples from each individual; fµ data from both groups were 
pooled to calculate an average value for all children.
In those infants in whom a consistent decline in plasma bupivacaine concentration with time was seen (Fig. 
1) an "apparent" terminal half-life (t1/2) was calculated using the equation: EQUATION
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Fig. 1. The individual plasma bupivacaine concentration-time profiles from all the infants in both the "plain" 
group and the "adrenaline" group.
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Equation 1
Statistical analysis
All data are stated as median (range). Between group comparison was made with Mann-Whitney's U-test. A 
P-value <0.05 was considered statistically significant.
Results
Fifteen ASA I or II children (all boys) were included in this study. Demographic details and surgical 
procedures are listed in Table 1. The duration of anaesthesia was comparable in both groups. In the "plain" 
group, the anaesthetic lasted a median of 35 min (range 25-70 min) as opposed to a median of 45 min (range 
30-55 min) in the "adrenaline" group. Similarly, the duration of surgery also was comparable in both groups. In 
the "plain" group, surgery lasted a median of 25 min (range 15-55 min) as opposed to a median of 32.5 min 
(range 20-45 min) in the "adrenaline" group. Seven infants received plain bupivacaine and eight infants received 
bupivacaine with adrenaline (1/400 000). The caudal blocks were considered successful in all infants as they 
achieved adequate intra- and postoperative analgesia. No clinical signs of systemic toxicity were seen in any 
infant. None of the infants required any additional analgesia during the study period.
Table 1 Demographic details, median (range). 
Overall, the total plasma bupivacaine concentrations in all but one sample were below 2 µg/ml. This
sample was taken at t=60 min in a 14-week-old term baby and found to be 2195 ng/ml. The total bupivacaine 
levels ranged between 114 ng/ml and 2196 ng/ml. No differences in the total plasma bupivacaine 
concentrations could be found at any of the time points from 30 min to 240 min. However, the median total 
bupivacaine concentration at t=360 min was significantly higher in the "adrenaline" group compared to the 
"plain" group, i.e. 742 ng/ml (372-1423 ng/ml) vs. 400.5 ng/ml (114-446 ng/ml), P=0.0080. No differences in 
CMAX or TMAX could be found between the groups. The plasma concentration-time profiles for both groups are 
shown in Fig. 1. The measurements of free bupivacaine were made on individual samples in 3 infants from both 
groups. Due to small numbers no differences were found in the free bupivacaine concentrations between the 
groups. Overall, the free levels remained fairly stable throughout the study period, ranging between 13 ng/ml 
and 52 ng/ml. The corresponding median percentage of free bupivacaine (fµ) was 2.8% (1.3-4.6%) in the "plain" 
and 3.2% (1.3-6.7%) in the "adrenaline" group. When looking at both groups, the combined median fµ was 3.0% 
(1.3-6.7%).
The median "apparent" terminal half-life (t 1/2) was found to be significantly longer in the "adrenaline" 
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group (n=5), i.e. 363 min (range 238-537 min) compared to 165 min (range 104-264 min) in the plain group (n=6), 
P=0.0087.
The pharmacokinetic parameters are detailed in Table 2.
Table 2 Pharmacokinetic parameters, median (range). 
Discussion
This is the first study describing the effects of adrenaline on the systemic absorption and pharmacokinetics 
of caudally administered bupivacaine in infants. Although the effects of adrenaline to a great extent depend on 
the site of the injection, it may also depend on the local anaesthetic agent, as well as the concentration used 
(15).
In theory, when using longer acting lipophilic local anaesthetic drugs such as bupivacaine, the effects of 
adrenaline tend to be less obvious than with hydrophilic drugs, such as lignocaine. It is believed that 
bupivacaine when injected epidurally will bind to the epidural fat and subsequently is released slowly. However, 
small babies have less epidural fat and a much higher cardiac output, and due to the relatively short-acting 
actions of adrenaline the systemic absorption lowering effects of adrenaline may be negligible (1, 15).
In this study, the total plasma bupivacaine concentrations measured were below 2 µg/ml in all but one
sample, irrespective of the group. Surprisingly, the addition of adrenaline to the local anaesthetic solution did 
not influence the CMAX obtained.
Interestingly, however, we were able to show a prolonged systemic absorption of bupivacaine in infants 
receiving a caudal block with 0.25% bupivacaine with 1:400 000 adrenaline compared to plain 0.25% bupivacaine. 
This was manifested by a significantly higher median total plasma bupivacaine concentration at t=360 min in 
the "adrenaline" group 742 ng/ml (range 372-1423 ng/ml) vs. 400.5 ng/ml (range 114-446 ng/ml) in the "plain" 
group. The resulting mean "apparent" terminal half-life, too, was significantly prolonged in the "adrenaline" 
group, i.e. 363 min (range 238-537 min) vs. 165 min (104-264 min) in the "plain" group.
The aim of this study was to investigate the effects of adrenaline on the systemic absorption of caudal 
bupivacaine and we did not attempt to estimate the clinical effects - if any.
In a study from 1988 by Mazoit et al., the pharmacokinetics of caudal bupivacaine was examined in 13 
infants aged 1-6 months of age. They found peak plasma concentrations (CMAX) of between 550 ng/ml and 1930 
ng/ml after 10-60 min (TMAX) and a mean terminal half-life (t 1/2) of 462 min (range 216-654 min). The mean 
free unbound bupivacaine concentration was 140 ng/ml (range 50-210 ng/ml) and the corresponding mean free 
fraction (fµ) was 0.16 (range 0.08-0.31) (5). In the present study the free bupivacaine concentrations were 
somewhat lower ranging between 13 ng/ml and 52 ng/ml, as were the corresponding fµ ranging between 1.3% 
and 6.7% (i.e. comparable to levels reported in adults). The reasons for this discrepancy may be many. First of 
all, the degree of binding varies significantly from individual to individual. Furthermore, intra-individually, the 
free levels may vary with the total levels. Since the [alpha]1-acid glycoprotein levels continue to rise 
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postoperatively (being an acute phase protein), the level of free drug might fall as the total level rises, 
depending on the relationship between the pharmacokinetics of the drug and the variation in [alpha]1-acid 
glycoprotein levels. In addition, problems associated with the different methodologies used may be of 
importance too. Basically, there are three methods, which are applicable to the measurement of the free and 
the bound form of a drug: equilibrium dialysis, ultrafiltration and microdialysis. All of these methods suffer from 
drawbacks. The extent of protein binding is a function of drug and protein concentrations, the affinity constant 
for the drug-protein interaction, and the number of protein binding sites per class of binding site. Ultimately, as 
in all methods, the question remains as to how much the separation process perturbs the equilibrium between 
the free and bound forms of the drug (13, 16). It must be stressed, however, that there are not many 
measurements in neonates and infants to compare with in the literature. In a recent work by our group, utilising 
micro-equilibrium dialysis, we have found that the free levels of bupivacaine are in the range of 2-2.5% in 
neonates, despite [alpha]1-acid glycoprotein levels being lower than in adults (Watson DG, personal 
communication). The problems of protein binding and bupivacaine in neonates/infants are an important issue 
that needs further attention.
In another study comprising older children (n=6) aged between 5.5 and 10 years of age, total CMAX values 
between 960 ng/ml and 1640 ng/ml at TMAX between 19.7 min and 38.4 min and a mean t 1/2 of 277 min 
(range 175-377 min) was reported (4).
The adrenaline concentration used in this study 1/400 000 (=2.5 µg/ml) was chosen for two reasons. Firstly,
the desired concentration of both bupivacaine and adrenaline was easily prepared from the manufacturer's 
solution of 0.5% bupivacaine with 1/200 000 adrenaline by diluting this solution 1:1 with normal saline prior to 
the caudal injection. Secondly, during the preparation of the project claims had been made as to direct toxic 
effects to the medulla from high local adrenaline concentrations, resulting in ischaemic injuries to the medulla 
(1, 15).
The sample size in this study was fairly small (n=15 in total) as were the numbers of blood samples taken. 
The latter was a restriction from our local Ethics Committee, which only allowed us to take a total volume of 
blood of 1 ml/kg for research purposes from each child. Our results, however, are in keeping with those of other 
investigators - albeit the median t 1/2 in this study was somewhat shorter at 165 min and 363 min, 
respectively, compared to the findings by Mazoit et al. (mean t 1/2=462 min) (5). By looking at Fig. 1, it seems 
obvious that the addition of adrenaline to bupivacaine results in a prolonged absorption phase within the study 
period. What happens beyond 360 min remains to be elucidated.
CMAX and TMAX are highly context dependent parameters, hence these results should be interpreted with 
caution, but the results in this study are not much different to those reported by other investigators.
In conclusion, this study using pharmacokinetic parameters confirms that the addition of 1/400 000 
adrenaline prolongs the systemic absorption of caudally administered bupivacaine in infants.
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Plasma paracetamol concentrations and pharmacokinetics following rectal 
administration in neonates and young infants
Abstract
Background: Despite widespread use in children pharmacokinetic data about paracetamol are relatively 
scarce, not the least in the youngest age groups. This study aimed to describe plasma paracetamol 
concentrations and pharmacokinetics of a single rectal paracetamol dose in neonates and young infants.
Methods: Perioperatively, 17 neonates and infants <=160 days of age received one rectal paracetamol dose 
(mean 23.9 mg/kg (±4.2 mg/kg)). Blood samples were drawn at 60, 120, 180, 240, 300 and 360 min, according to
the infants' weights. Plasma paracetamol concentrations were measured by a Colorometric Assay, Ectachem 
Clinical Chemistry Slides (Johnson & Johnson Clinical Diagnostics).
Results: The plasma paracetamol concentrations were mainly below the therapeutic (i.e. antipyretic) range 
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of 66-132 µmol/l and did not exceed 160 µmol/l in any infant. The mean maximum plasma concentration (Cmax) 
was 72.4 µmol/l (±33.5 µmol/l) and the time to Cmax, i.e. the mean Tmax was 102.4 min (±59.1 min). The mean
"apparent" terminal half-life (n=10) was 243.6 min (±114.1 min).
Conclusion: The absorption of rectal paracetamol (mean dose 23.9 mg/kg, ±4.2mg/kg) in young infants <160
days is variable and often prolonged and achieves mainly subtherapeutic plasma concentrations.
Paracetamol is the most widely used analgesic and antipyretic in children. It is a drug with few 
contraindications and few adverse effects when used in recommended doses. In addition, it can be administered 
by the oral, rectal and intravenous routes (1-4). Paracetamol acts by inhibiting peripheral and central 
prostaglandin synthesis but, unlike the non-steroidal anti-inflammatory drugs (NSAIDS), it has weak 
anti-inflammatory properties (5). A "ceiling effect" is seen for analgesia with paracetamol (6).
The plasma paracetamol concentration range associated with an anti-pyretic effect is 66-132 µl/l (10-20
mg/l; conversion factor is 6.6 µmol/mg) (1,2). The optimal analgesic plasma concentration range may be 
somewhat higher, but has not been clearly defined (7).
Hepatotoxicity occurs when peak plasma concentration is approximately 10-times this level, at around 990
µmol/l (8). The minimum potentially toxic single dose in children has been calculated as 150 mg/kg (9), but may 
be less in those with renal disease, hepatic disease, dehydration or malnutrition.
When administered orally, paracetamol is well absorbed within 30-60 min and therapeutic plasma 
concentrations are maintained for 2-4 h after a single dose of 15-20 mg/kg (10). After rectal administration, the 
relative bioavailability is poor and absorption is slow and erratic with an average time to reach maximum 
plasma concentration (Tmax) of 2.3 h (3,8,11-14). It has been demonstrated that a rectal loading dose of 40-45 
mg/kg is needed to achieve and sustain therapeutic plasma concentrations in children older than 1 year 
(7,14,15). However, pharmacokinetic data are sparse in the youngest age groups (4,13,16-18), and our study 
aimed to describe the plasma concentration time profile and pharmacokinetics of a single rectal dose of 
paracetamol in neonates and young infants.
Methods
Following ethical approval and written informed parental consent, neonates and infants less than 160 days 
of age scheduled for minor surgery were enrolled in the study. Infants who had received paracetamol within the 
previous 24 h were excluded, as were infants with any known renal or hepatic impairments. After induction, but 
before the start of surgery, all infants received a single rectal paracetamol dose of approximately 25 mg/kg. The 
paracetamol (Alvedon®, Novex Pharma Ltd., Marlow, UK) given was formulated in a stearate-based suppository
and used in a strength of either 60 mg or 125 mg.
Anaesthetic technique
Apart from EMLA, no premedication was given and all infants received a standardized non-opioid-based 
general anaesthetic technique, supplemented with an appropriate regional block.
The general anaesthetic technique comprised induction with thiopenthone (3-5 mg/kg) and suxamethonium 
(1.0-1.5 mg/kg) or atracurium (0.5 mg/kg). Following endotracheal intubation, the infants' lungs, were 
ventilated to normocapnia with 50% oxygen in nitrous oxide and desflurane. Eleven infants received a caudal 
block with bupivacaine 0.25% (1.0 ml/kg), 4 infants received wound infiltration with bupivacaine 0.25% (0.25-0.5 
ml/kg) and 1 infant received local anaesthetic eye drops with amethocaine 0.5%. One infant did not receive any 
local anaesthesia. No infants required any further analgesics during the study period.
After surgery, residual neuromuscular blockade was reversed with glycopyrrolate (10 µg/kg) and neostigmine
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(50 µg/kg) and all children were extubated.
Blood sampling
Immediately after the anaesthetic induction, a dedicated peripheral intravenous cannula (venflon 22 G, 
Ohmeda, Sweden) was inserted in a saphenous vein for blood sampling. Patency of this cannula was maintained 
by an infusion of 5% glucose with 0.225% saline 3-5 ml/h.
Blood samples (0.7-1.0 ml/sample) were collected from the i.v. cannula at 60, 120, 180, 240, 300 and 360 
min after the administration of the suppository. The total number of blood samples from each individual was 
restricted by the Ethics Committee's limit of 1 ml/kg, but it was possible to sample all infants at 60, 120 and 
360 min. Older infants had additional samples drawn at intermediate time points according to weight. Blood 
samples were separated by centrifugation and the plasma was stored at -20°C until assay.
Paracetamol analysis
Plasma paracetamol levels were measured by a commercially available Colorometric Assay, the Ectachem 
Clinical Chemistry Slides (ACET) (Johnson & Johnson Clinical Diagnostics, Inc., New York, USA) according to the 
manufacturer's instruction. The accuracy of this method has been shown over a wide range of concentrations 
when compared with both a high-performance liquid chromatography (HPLC) and a fluorescence polarization 
reference technique. The sensitivity-limit of the assay was 25 µmol/l and the intraassay and interassay
coefficient of variation of the method was <5%. No drugs known to interfere with the assay were given to any 
infants.
Pharmacokinetics
For each infant, we determined maximal plasma concentration (Cmax) and time to maximal plasma 
concentration (Tmax). Due to erratic or delayed absorption, the limited number of samples taken and the short 
duration of sampling time, we were unable to calculate detailed pharmacokinetic parameters in this study. 
However, in 10 infants in whom a consistent decline in plasma paracetamol with time was seen (Fig. 1), we 
calculated an "apparent" terminal half-life (t½), using the equation: k e=(lnC1-lnC2)/T2-T1 = [DELTA]lnC/[DELTA]T 
[right double arrow] t½=ln2/k e, from two or more data points between 60 and 360 min, assuming a terminated 
absorption phase.
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Fig. 1. The individual plasma paracetamol concentration-time profiles following rectal administration of 23.9 
mg/kg (±4.1 mg/kg) paracetamol in neonates and infants, omitting plasma levels <25 µmol/l.
The Cmax obtained was correlated to the actual paracetamol dose given (range 17.6-32.8 mg/kg) using 
linear regression.
Data are stated as mean (±SD). A P-value <0.05 was considered statistically significant.
Results
Seventeen neonates and young infants <=160 days of age were enrolled in this study (3 girls and 14 boys). 
Their mean postnatal ages were 71.5 days (±47 days) and their corresponding mean weights were 3.9 kg (±1.4
kg). Eight children had been born prematurely. Their mean gestational ages at birth were 32.6 weeks (±2.6
weeks) and at the time of the study their mean postconceptual ages were 39.8 weeks (±3.7 weeks).
Demographic details and surgical procedures are listed in Table 1.
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Table 1 Demographic data.
The mean paracetamol dose administered to the infants in this study was 23.9 mg/kg (±4.2 mg/kg). The
resulting plasma paracetamol concentration/time profile for each individual is shown in Fig. 1. The plasma 
concentrations were mainly below the therapeutic "antipyretic" range and did not exceed 160 µmol/l in any
infant (Fig. 1). The mean Cmax was 72.4 µmol/l (±33.5 µmol/l) and the corresponding time to obtain Cmax, i.e. 
the mean Tmax, was 102.4 min (±59.1 min). In those 10 infants in whom we were able to calculate an "apparent"
terminal half-life (t½), we found a mean t½ of 243.6 min (±114.1 min).
The relationship between Cmax and the actual paracetamol dose given is shown in Fig. 2
(Cmax=2.71×Dose+1.52; r
2=0.264, P<0.05).
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Fig. 2. The relationship between the actual paracetamol dose given (range 17.6-32.8 mg/kg) and the Cmax
obtained (Cmax=2.71×Dose+1.52; r
2=0.264, P<0.05).
Discussion
This study showed an incomplete or delayed absorption of 23.9 mg/kg (±4.2 mg/kg) rectal paracetamol in
young infants <=160 days of age. The resulting mean plasma concentrations were subtherapeutic (i.e. less than 
66-132 µmol/l). The mean Cmax was 72.4 µmol/l (±33.5 µmol/l) and the corresponding time to obtain Cmax, i.e. 
the mean Tmax was 102.4 min (±59.1 min). The accuracy of the pharmacokinetic data obtained in this study may
be somewhat unreliable due to the limited number of blood samples in many of the children. However, the 
results are in keeping with those of other investigators, though comprising mainly older children (4,7,11-16). 
Following rectal paracetamol doses of 18.1 mg/kg (13) and 20 mg/kg (16), mean Cmax levels of 52.1 µmol/l and
55.4 µmol/l at Tmax of 58 min and 78 min have been demonstrated in 2 studies comprising 9 and 5 neonates, 
respectively. In another study comprising 10 infants receiving a mean rectal paracetamol dose of 17.9 mg/kg, a 
mean Cmax of 37.6 µmol/l at a Tmax of 78 min was obtained (13).
We were able to estimate an "apparent" mean terminal half-life of 243.6 min (±114.1 min) in 10 of the
infants studied. We must emphasize that the assumption held for the t½ calculated in this study, i.e. a
completed absorption phase before T1 and T2, may not necessarily be fulfilled. However, application of the 
Wagner-Nelson method (19) to the profiles from 8 of these 10 patients gives a mean absorption half-life of 18.7 
min (±9.9 min). This indicates that when the elimination constant is calculated from data points from 120 min
and onwards, 99% of the absorption has already occurred. Furthermore, our results are comparable to previous 
studies comprising neonates and young infants reporting mean elimination half-lives of 168-294 min 
(4,13,17,18). Interestingly, in infancy shorter elimination half-lives have been reported (96-126 min) (13,17).
Several factors may contribute to the incomplete or delayed absorption of rectal paracetamol. The relative 
bioavailability of a suppository may furthermore depend on the formulation, i.e. the absorption of lipophilic 
suppositories are more rapid than that of hydrophilic suppositories (21). The height in the rectum may be 
Ovid: Plasma paracetamol concentrations and pharmacokinetics fo... http://ovidsp.uk.ovid.com/spb/ovidweb.cgi
7 of 8 5/7/08 15:59
important in small children. The suppository is relatively large in relation to the rectum of the smaller infant. 
This could mean that a major part is absorbed via the superior rectal venous drainage directly into the portal 
vein and thus undergo a significant first-pass hepatic clearance. Other factors known to interfere with rectal 
absorption of drugs are: pH, defaecation, the contents of the rectal vaults and the colonic blood flow. The 
anaesthetics (mainly the inhalational agents) may reduce the colonic blood flow and thereby delay absorption 
(3,4,7,12,15).
Furthermore, the rate at which suppositories dissolve may be a function of suppository dose size, in that 
smaller dose suppositories dissolve more rapidly (11). Interestingly, high rectal paracetamol doses are not 
accompanied by a shorter Tmax (7,11,14,15).
In conclusion, the absorption of 23.9 mg/kg (±4.2 mg/kg) of rectally administered paracetamol is variable
and often prolonged in young infants <=160 days of age. The resulting plasma concentrations are mainly 
subtherapeutic and the mean "apparent" terminal t½ is 243.6 min (±114.1 min).
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Summary
Background: Remifentanil is a short acting, potent synthetic opioid that
does not accumulate after infusion or repeated bolus doses. It may be
rapidly titrated to the requirements of individual patients. Titrated
infusion of remifentanil may be able to provide potent analgesia
required for pediatric cardiac surgery and obtund the stress response
in theater whilst not having the persistent respiratory depression and
sedation seen with longer acting opioids.
Methods: Twenty patients were randomized to receive a titrated
infusion of remifentanil (0–1 lgÆkg)1Æmin)1) or a standard dose of
fentanyl (30 lgÆkg)1) prebypass plus morphine (1 mgÆkg)1) on re-
warming. Blood samples for glucose and cortisol were taken at regular
intervals from induction through bypass and into the first 24 h of
postoperative intensive care. In addition to biochemical indicators of
the stress response we recorded baseline hemodynamic parameters
and any acute physiological events.
Results: Ten patients received morphine, seven received remifentanil.
There were no statistically significant differences between the two
treatment groups in cortisol measurements, mean arterial pressure or
heart rate recordings. In the last time period the remifentanil group
had a larger rise in blood glucose concentration (baseline 3.9, rise
3 mmolÆl)1) than the fentanyl/morphine group (baseline 4.2 rise
1.9 mmolÆl)1), CI )4.3 to )0.2.
Conclusions: The only significant difference was in glucose in the
postbypass time periods. Although statistically significant, this dif-
ference is insufficient evidence of increased stress in the remifentanil
group. The results show that in the patients studied there was no
clinically important difference between the two techniques.
Keywords: congenital heart disease; remifentanil; stress response
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Introduction
Remifentanil is a selective l-opioid receptor agonist.
A synthetic piperidine derivative, it is around 16
times more potent than alfentanil (1). Nonspecific
tissue and plasma esterases hydrolyze remifentanil
into metabolites that are excreted by the kidney and
have no significant clinical actions. The biological
half-life of remifentanil is between 3 and 10 min; it
has a fast onset of action and does not accumulate
after infusion or repeated bolus administration (2),
(3). These characteristics combine to give a theoret-
ical clinical advantage of a potent opioid that can be
rapidly titrated to meet the immediate clinical
requirement and obtund the stress response to
surgical stimulus, without persistent effects that
may delay postoperative progress.
Methods
After approval by the local ethics committee, 20
patients who were scheduled for open-heart sur-
gery were randomized to one of two treatment
groups. Apart from the choice of opioid analgesia
used, the anesthetic technique was that normally
used by the consultant anesthetist in charge of the
case. All patients had 5% glucose with saline 0.45%
commenced before rewarming from cardiopulmon-
ary bypass. Patients were excluded if they received
steroids, or glucose infusions before cardiopulmon-
ary bypass. The fentanyl and morphine group had
a standard dose of fentanyl (30 lgÆkg)1) increment-
ally prior to institution of cardiopulmonary bypass.
This group also received morphine (1 mgÆkg)1) on
rewarming and had a morphine infusion com-
menced on admission to the intensive care unit.
The remifentanil group received a remifentanil
infusion (at a rate of 0–1 lgÆkgÆmin)1 and additional
boluses of 1 lgÆkg)1 if required), titrated to the
patients’ clinical requirement as judged by the
anesthetist present. This infusion was given
through an additional peripheral intravenous line
inserted solely for that purpose. It was intended to
continue the remifentanil infusion for 24 h on the
intensive care unit, but the infusion could be
exchanged for morphine at the discretion of inten-
sive care staff. The remifentanil was continued post
bypass as it was proposed that there may be
advantages in titrating opioid requirements in the
postbypass period and not because there was any
attempt or desire to extubate the patient earlier in
the postoperative period than those patients receiv-
ing fentanyl/morphine.
Heart rate and mean arterial pressure were recor-
ded and averaged over time. In addition to these
physiological variables, acute events such as tachy-
cardia, bradycardia, or any changes that may have
related to excessive or inadequate analgesia were
recorded. Blood samples for glucose and cortisol
were taken at regular intervals from before induc-
tion of anesthesia into the period of postoperative
intensive care. Immediately after collection the
specimens for cortisol were centrifuged and the
serum was withdrawn for analysis.
For analysis purposes data were divided into
three time periods: prebypass; during bypass and
postbypass until admission to the intensive care
unit.
For each biochemical or physiological parameter,
the first recorded value was chosen as the baseline.
This was a preinduction recording or sample in
almost all cases. When it was not possible to
withdraw blood from the peripheral cannula inser-
ted with the child awake, a sample taken immedi-
ately postinduction was used as the baseline. The
change from the baseline value to the maximum
recorded value during each of the three time
periods, was calculated. These changes were com-
pared between the two groups using Mann–Whitney
tests (a ¼ 0.05, unadjusted for multiple compari-
sons). All analyses were carried out using the
statistical analysis package MINITAB Version 12.
Results
There were two late cancellations in the remifentanil
group and one patient was also withdrawn from this
group because of a protocol violation. One patient in
the remifentanil group developed a junctional ecto-
pic tachycardia following repair of an atrioventricu-
lar septal defect. Postoperative heart rate recordings
were excluded from analysis for this patient. The
details of cases presenting for surgical repair and the
anesthetic techniques used are listed in Table 1.
Postbypass, patients in the remifentanil group had
significantly higher glucose levels than those who
received fentanyl/morphine [median difference
from baseline )2.2, CI ()4.3, )0.2)] as shown in
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Figure 1. There were no statistically significant
differences between the two groups for other vari-
ables in any time period as illustrated in Figures 2, 3
and 4.
Two acute events occurred in the remifentanil
group. One patient moved as cardiopulmonary
bypass was commenced, requiring a bolus of rem-
ifentanil. This patient had received a single dose of
vecuronium at induction, which had obviously worn
off. Another patient became unsettled during trans-
fer to intensive care. This was because of a kink in
the peripheral cannula being used for the remifent-
anil infusion. Both of these events were accompan-
ied by physiological change but neither caused
identifiable changes in the biochemical measures of
the stress response.
Four patients continued remifentanil infusions for
24 h in intensive care, the remaining three were
converted to infusions of morphine during this
period.
All patients were alive at routine follow up 1 year
postoperatively.
Discussion and Conclusions
We conclude that the two techniques using either
fentanyl/morphine or remifentanil produced
broadly similar perioperative control of the stress
response during open-heart surgery in children.
Change from baseline measurement of heart rate,
mean arterial pressure and serum cortisol were
similar in both groups. Glucose levels were also
similar before and during bypass, but were raised
following bypass in the remifentanil group.
Although statistically significant, we do not feel this
change in glucose is clinically important. Taken
Table 1
Details of cases presenting for repair and anesthetic technique
Operation Age (months) Preoperative condition/diagnoses Anesthetic technique
Fentanyl and morphine group n ¼ 10
Tetralogy of Fallot repair 17 Desaturation on exertion
supravalvular stenosis
Ketamine/rocuronium/isoflurane
Secundum atrial septal defect closure 48 Asymptomatic Propofol/rocuronium/isoflurane
Sub aortic myectomy 28 Outflow tract gradient 80 mmHg Sevoflurane/pancuronium/isoflurane
Tetralogy of Fallot repair 18 Good LV function, moderate right
ventricular outflow tract obstruction
Ketamine/Vecuronium/Isoflurane
Atrial septectomy 39 Double outlet right ventricle,
Glenn shunt planned but
pulmonary pressure too high
Thiopentone/vecuronium/isoflurane
Ventricular septal defect closure 7 Presented with lethargy,
pulmonary hypertension
Thiopentone/pancuronium/isoflurane
Ventricular septal defect closure 12 Presented with lethargy and failure
to thrive, previous pulmonary
artery band and coarctation repair
Sevoflurane/vecuronium/isoflurane
Ventricular septal defect closure 5 Presented with lethargy, pulmonary
hypertension
Thiopentone/vecuronium/isoflurane
Atrioventricular septal defect repair 4 Downs syndrome, pulmonary
hypertension
Sevoflurane/vecuronium/isoflurane
Secundum atrial septal defect closure 44 Moderate tricuspid regurgitation
and partial anomalous
pulmonary venous drainage
Propofol/pancuronium/isoflurane
Remifentanil group n ¼ 7
Secundum atrial septal defect closure 48 Low saturation, left superior vena cava Propofol/pancuronium/isoflurane
Secundum atrial septal defect closure 35 Right ventricular enlargement Thiopentone/pancuronium/isoflurane
Secundum atrial septal defect closure 35 Asymptomatic Thiopentone/vecuronium/isoflurane
Secundum atrial septal defect closure 48 Mitral regurgitation & pulmonary stenosis Thiopentone/vecuronium/isoflurane
Glenn shunt 53 Double outlet right ventricle, cyanosed,
hypoplastic left ventricle, previous
pulmonary artery band
Ketamine/vecuronium/isoflurane
Atrioventricular septal defect repair 3 Downs syndrome, in cardiac failure Thiopentone/pancuronium/isoflurane
Secundum atrial septal defect closure 108 Downs syndrome, right
ventricular enlargement
Thiopentone/vecuronium/isoflurane
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alone a small rise in glucose is insufficient to indicate
that the remifentanil patients were significantly
more stressed than those in the fentanyl/morphine
group.
It was intended to continue infusion of remifent-
anil for the first 24 h of intensive care. However, the
majority of patients were converted to morphine
infusions because of difficulty in achieving satisfac-
tory sedation and analgesia, whilst also reestablish-
ing spontaneous breathing. We would not
recommend remifentanil infusion for sedation in
the intensive care unit. The clearance of remifentanil
is moderately increased in the postbypass period (4)
this may contribute to the difficulty in selecting the
required dose. There is interest in using remifentanil
to facilitate early postoperative extubation but our
study was not designed to assess the feasibility or
timing of extubation.
The patient who moved when cardiopulmonary
bypass was started highlights the large interindi-
vidual variation in dosage requirements. This
patient was receiving the maximum rate of infusion
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Figure 4
Box and whisker plot of change in mean arterial pressure vs
perioperative time period. Boxes represent interquartile range and
whiskers represent maximal points that are not outliers. Asterisks
represent points that are >1.5 times the interquartile range.
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Figure 2
Box and whisker plot of change in serum cortisol vs perioperative
time period. Boxes represent interquartile range and whiskers
represent maximal points that are not outliers. Asterisks represent
points that are >1.5 times the interquartile range.
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Figure 1
Box and whisker plot of change in serum glucose vs perioperative
time period. Boxes represent interquartile range and whiskers
represent maximal points that are not outliers.
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Figure 3
Box and whisker plot of change heart rate vs perioperative time
period. Boxes represent interquartile range and whiskers repre-
sent maximal points that are not outliers.
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used in our study and supplemental isoflurane.
Although this dose has been found to be the ED50
for noncardiac surgery (5) using N2O, O2 and
remifentanil technique, a rate of 1 lgÆkg)1Æmin)1 is
not sufficient for all patients when the dilutional
effects of cardiopulmonary bypass are imposed.
Studies using remifentanil in combination with
isoflurane for noncardiac surgery have found the
average infusion rate required was 0.25 lgÆkg)1Æ
min)1 (6).
Another practical problem was illustrated by the
patient who moved when the infusion line was
kinked. We would recommend that remifentanil
infusions be given through a central line, when
available to reduce the possibility of this happening.
None of our study patients had bradycardia or
hypotension although we commenced the remifent-
anil at a rate of 1 lgÆkgÆmin)1 in most cases. This
contrasts with findings in infants undergoing
abdominal surgery (7).
Although we did not perform statistical analysis
on the data once the patients had been admitted to
the intensive care unit as the differences in treatment
would have made the groups incomparable, patients
from both groups showed similar patterns with
serum cortisol measurements peaking around 18 h
after admission to the intensive care unit. It may well
be the case that both techniques simply delay the
stress response as has been shown previously with
other high dose opioid techniques.
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